ticker stringlengths 1 5 | text stringlengths 113 10.8k | publisher stringclasses 67
values | timestamp timestamp[ns] | title stringlengths 7 494 | url stringlengths 53 141 | uuid stringlengths 36 36 | partial_article bool 1
class | prompt stringlengths 292 11k | token_count int64 69 2k | valid_ticker bool 1
class | open float64 0.13 6.4k | close_1 float64 0.14 6.47k | close_2 float64 0.11 6.47k | close_3 float64 0.1 6.45k | close_4 float64 0.04 6.35k | close_5 float64 0.02 6.35k | result_1 stringclasses 2
values | result_2 stringclasses 2
values | result_3 stringclasses 2
values | result_4 stringclasses 2
values | result_5 stringclasses 2
values | result_1_bin int64 0 1 | result_2_bin int64 0 1 | result_3_bin int64 0 1 | result_4_bin int64 0 1 | result_5_bin int64 0 1 | relevance stringclasses 5
values | __index_level_0__ int64 0 15.3k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
A | Vipshop Holdings Limited VIPS is set to report first-quarter 2023 results on May 23.VIPS expects first-quarter total net revenues between RMB 25.2 billion and RMB 26.5 billion, indicating growth of 0-5% from the prior-year quarter’s reported figure.The Zacks Consensus Estimate for revenues is pegged at $3.77 billion, suggesting a decline of 5.3% from the year-ago reported figure.The consensus mark for earnings per share is pegged at 39 cents per share, indicating growth of 18.2% from the prior-year reported figure.Vipshop’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average earnings surprise being 22.91%.Vipshop Holdings Limited Price and EPS SurpriseVipshop Holdings Limited Price and EPS SurpriseVipshop Holdings Limited price-eps-surprise | Vipshop Holdings Limited QuoteKey Factors at PlayVipshop’s growing efforts to strengthen product offerings and improve product procurement are expected to have benefited its first-quarter performance.Solid execution of Vipshop’s merchandising strategy is likely to have bolstered its total active customer base in the to-be-reported quarter.VIPS’ quarterly results are expected to reflect its deepening focus on high-margin apparel-related businesses, especially the discount apparel business.The business is expected to have accelerated Vipshop’s gross merchandise volume (GMV) in the quarter under review.Additionally, its successful transition to discount retailing remains a major positive. This is anticipated to have continued driving the momentum across repeated customers and helped attract new ones.VIPS’ deep discount channels are expected to have bolstered its online GMV in the to-be-reported quarter.However, weakening consumer demand in discretionary categories due to the challenging macroenvironment in China might have been a negative.Also, the impacts of intensifying competition in the online shopping market are anticipated to get reflected in the upcoming results of Vipshop.Story continuesWhat Our Model SaysOur proven model doesn’t conclusively predict an earnings beat for Vipshop this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here, as you see below.Vipshop has a Zacks Rank #2 and an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Stocks to ConsiderHere are some stocks worth considering, as our model shows that they have the right combination of elements to beat on earnings this season.Autodesk ADSK has an Earnings ESP of +1.76% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.ADSK is scheduled to release first-quarter 2024 results on May 25. The Zacks Consensus Estimate for ADSK’s earnings is pegged at $1.55 per share, suggesting a rise of 8.4% year over year.Agilent Technologies A has an Earnings ESP of +0.40% and currently carries a Zacks Rank #2.Agilent Technologies is set to report second-quarter fiscal 2023 results on May 23. The Zacks Consensus Estimate for A’s earnings is pegged at $1.27 per share, implying a 12.4% increase from the prior-year quarter’s reported figure.Costco Wholesale COST has an Earnings ESP of +0.04% and a Zacks Rank #3 at present.COST is scheduled to report third-quarter fiscal 2023 results on May 25. The Zacks Consensus Estimate for COST’s earnings is pegged at $3.32 per share, suggesting an increase of 4.7% from the prior-year quarter’s reported figure.Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportCostco Wholesale Corporation (COST) : Free Stock Analysis ReportAutodesk, Inc. (ADSK) : Free Stock Analysis ReportVipshop Holdings Limited (VIPS) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | 2023-05-18T16:14:04 | Vipshop (VIPS) to Post Q1 Earnings: What's in the Offing? | https://finance.yahoo.com/news/vipshop-vips-post-q1-earnings-161404714.html | 27293957-38d0-3710-8e36-c33a88428202 | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "Vipshop Holdings Limited VIPS is set to report first-quarter 2023 results on May 23.VIPS expects first-quarter total net revenues between RMB 25.2 billion and RMB 26.5 billion, indicating growth of 0-5% from the prior-year quarter’s reported figure.The Zacks Consensus Estimate for revenues is pegged at $3.77 billion, suggesting a decline of 5.3% from the year-ago reported figure.The consensus mark for earnings per share is pegged at 39 cents per share, indicating growth of 18.2% from the prior-year reported figure.Vipshop’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average earnings surprise being 22.91%.Vipshop Holdings Limited Price and EPS SurpriseVipshop Holdings Limited Price and EPS SurpriseVipshop Holdings Limited price-eps-surprise | Vipshop Holdings Limited QuoteKey Factors at PlayVipshop’s growing efforts to strengthen product offerings and improve product procurement are expected to have benefited its first-quarter performance.Solid execution of Vipshop’s merchandising strategy is likely to have bolstered its total active customer base in the to-be-reported quarter.VIPS’ quarterly results are expected to reflect its deepening focus on high-margin apparel-related businesses, especially the discount apparel business.The business is expected to have accelerated Vipshop’s gross merchandise volume (GMV) in the quarter under review.Additionally, its successful transition to discount retailing remains a major positive. This is anticipated to have continued driving the momentum across repeated customers and helped attract new ones.VIPS’ deep discount channels are expected to have bolstered its online GMV in the to-be-reported quarter.However, weakening consumer demand in discretionary categories due to the challenging macroenvironment in China might have been a negative.Also, the impacts of intensifying competition in the online shopping market are anticipated to get reflected in the upcoming results of Vipshop.Story continuesWhat Our Model SaysOur proven model doesn’t conclusively predict an earnings beat for Vipshop this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here, as you see below.Vipshop has a Zacks Rank #2 and an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Stocks to ConsiderHere are some stocks worth considering, as our model shows that they have the right combination of elements to beat on earnings this season.Autodesk ADSK has an Earnings ESP of +1.76% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.ADSK is scheduled to release first-quarter 2024 results on May 25. The Zacks Consensus Estimate for ADSK’s earnings is pegged at $1.55 per share, suggesting a rise of 8.4% year over year.Agilent Technologies A has an Earnings ESP of +0.40% and currently carries a Zacks Rank #2.Agilent Technologies is set to report second-quarter fiscal 2023 results on May 23. The Zacks Consensus Estimate for A’s earnings is pegged at $1.27 per share, implying a 12.4% increase from the prior-year quarter’s reported figure.Costco Wholesale COST has an Earnings ESP of +0.04% and a Zacks Rank #3 at present.COST is scheduled to report third-quarter fiscal 2023 results on May 25. The Zacks Consensus Estimate for COST’s earnings is pegged at $3.32 per share, suggesting an increase of 4.7% from the prior-year quarter’s reported figure.Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportCostco Wholesale Corporation (COST) : Free Stock Analysis ReportAutodesk, Inc. (ADSK) : Free Stock Analysis ReportVipshop Holdings Limited (VIPS) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research"
Output: | 1,008 | true | 129.589996 | 128.869995 | 129.089996 | 128.639999 | 120.989998 | 119.489998 | DOWN | DOWN | DOWN | DOWN | DOWN | 0 | 0 | 0 | 0 | 0 | TRUE | 0 |
A | Fourth-quarter revenue declined by 8.7% reported and 9.7% core year-over-year.GAAP EPS increased by 32% in Q4, while non-GAAP EPS decreased by 10% compared to the same period last year.Full fiscal year 2023 revenue remained flat, with a slight core increase of 1.5% year-over-year.Agilent's fiscal year 2024 outlook anticipates a slow recovery with revenue expected to range between $6.71 billion and $6.81 billion.Warning! GuruFocus has detected 6 Warning Sign with GBDC.On November 20, 2023, Agilent Technologies Inc (NYSE:A) released its 8-K filing, detailing the financial results for the fourth quarter and full fiscal year 2023. The company reported a fourth-quarter revenue of $1.69 billion, which represents an 8.7% decrease on a reported basis and a 9.7% decrease on a core basis from the fourth quarter of 2022. Despite the revenue decline, Agilent's GAAP net income rose to $475 million, with earnings per share (EPS) climbing to $1.62, a 32% increase from the previous year's quarter. However, non-GAAP net income saw a decrease, with EPS dropping by 10% to $1.38.Fiscal Year 2023 Performance OverviewFor the full fiscal year 2023, Agilent's revenue remained flat at $6.83 billion on a reported basis but showed a modest core increase of 1.5% year-over-year. The GAAP net income for the year was $1.240 billion, with EPS remaining steady at $4.19. The non-GAAP net income for the year was $1.609 billion, with a 4% increase in EPS to $5.44.Segment Performance and OutlookThe Life Sciences and Applied Markets Group (LSAG) experienced a significant revenue decline of 17% reported and 18% core year-over-year in Q4, with a full-year revenue decrease of 4% reported and 2% core. Conversely, the Agilent CrossLab Group (ACG) saw a 6% reported and 4% core increase in Q4 revenue, with an 8% reported and 10% core growth for the full year. The Diagnostics and Genomics Group (DGG) reported a slight 1% increase in revenue on a reported basis and remained flat on a core basis for both the quarter and the full year.Story continuesLooking ahead to fiscal year 2024, Agilent expects revenue to be in the range of $6.71 billion to $6.81 billion, which would represent a slight decline to a marginal increase on a reported basis and a core basis, respectively. The non-GAAP EPS is projected to be between $5.44 and $5.55. For the fiscal first quarter, revenue is anticipated to decline by 11.4% to 8.6% reported and 11.3% to 8.5% core, with non-GAAP earnings guidance expected to be in the range of $1.20 to $1.23 per share.Financial Statements HighlightsAgilent's balance sheet as of October 31, 2023, shows an increase in total assets to $10.763 billion, up from $10.532 billion the previous year. The company's cash and cash equivalents also rose to $1.590 billion, compared to $1.053 billion in 2022. The condensed consolidated statement of cash flows indicates a net cash provided by operating activities of $1.772 billion for the year ended October 31, 2023, a notable increase from $1.312 billion in the previous year.Management Commentary"The Agilent team continued its strong execution in Q4 and delivered leveraged earnings in 2023 during a challenging year for the industry," said President and CEO Mike McMullen. "As we look ahead to 2024, we anticipate a slow but steady recovery. We have high confidence in the markets in which we have invested, the strength and resilience of our team, and the benefits of our build and buy growth strategy. Agilent is well-positioned for long-term growth."Agilent's financial performance in the fourth quarter and full fiscal year 2023 reflects the company's resilience in a challenging market. While certain segments experienced declines, others showed growth, and the company's overall financial health remains robust. Investors and stakeholders can look forward to a cautious but optimistic outlook for the coming fiscal year.Explore the complete 8-K earnings release (here) from Agilent Technologies Inc for further details.This article first appeared on GuruFocus. | GuruFocus.com | 2023-11-20T21:41:24 | Agilent Technologies Inc (A) Reports Mixed Fiscal Year 2023 Results Amid Industry Challenges | https://finance.yahoo.com/news/agilent-technologies-inc-reports-mixed-214124027.html | 3656149b-9b19-370c-bef5-03fa9c016fd5 | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "Fourth-quarter revenue declined by 8.7% reported and 9.7% core year-over-year.GAAP EPS increased by 32% in Q4, while non-GAAP EPS decreased by 10% compared to the same period last year.Full fiscal year 2023 revenue remained flat, with a slight core increase of 1.5% year-over-year.Agilent's fiscal year 2024 outlook anticipates a slow recovery with revenue expected to range between $6.71 billion and $6.81 billion.Warning! GuruFocus has detected 6 Warning Sign with GBDC.On November 20, 2023, Agilent Technologies Inc (NYSE:A) released its 8-K filing, detailing the financial results for the fourth quarter and full fiscal year 2023. The company reported a fourth-quarter revenue of $1.69 billion, which represents an 8.7% decrease on a reported basis and a 9.7% decrease on a core basis from the fourth quarter of 2022. Despite the revenue decline, Agilent's GAAP net income rose to $475 million, with earnings per share (EPS) climbing to $1.62, a 32% increase from the previous year's quarter. However, non-GAAP net income saw a decrease, with EPS dropping by 10% to $1.38.Fiscal Year 2023 Performance OverviewFor the full fiscal year 2023, Agilent's revenue remained flat at $6.83 billion on a reported basis but showed a modest core increase of 1.5% year-over-year. The GAAP net income for the year was $1.240 billion, with EPS remaining steady at $4.19. The non-GAAP net income for the year was $1.609 billion, with a 4% increase in EPS to $5.44.Segment Performance and OutlookThe Life Sciences and Applied Markets Group (LSAG) experienced a significant revenue decline of 17% reported and 18% core year-over-year in Q4, with a full-year revenue decrease of 4% reported and 2% core. Conversely, the Agilent CrossLab Group (ACG) saw a 6% reported and 4% core increase in Q4 revenue, with an 8% reported and 10% core growth for the full year. The Diagnostics and Genomics Group (DGG) reported a slight 1% increase in revenue on a reported basis and remained flat on a core basis for both the quarter and the full year.Story continuesLooking ahead to fiscal year 2024, Agilent expects revenue to be in the range of $6.71 billion to $6.81 billion, which would represent a slight decline to a marginal increase on a reported basis and a core basis, respectively. The non-GAAP EPS is projected to be between $5.44 and $5.55. For the fiscal first quarter, revenue is anticipated to decline by 11.4% to 8.6% reported and 11.3% to 8.5% core, with non-GAAP earnings guidance expected to be in the range of $1.20 to $1.23 per share.Financial Statements HighlightsAgilent's balance sheet as of October 31, 2023, shows an increase in total assets to $10.763 billion, up from $10.532 billion the previous year. The company's cash and cash equivalents also rose to $1.590 billion, compared to $1.053 billion in 2022. The condensed consolidated statement of cash flows indicates a net cash provided by operating activities of $1.772 billion for the year ended October 31, 2023, a notable increase from $1.312 billion in the previous year.Management Commentary"The Agilent team continued its strong execution in Q4 and delivered leveraged earnings in 2023 during a challenging year for the industry," said President and CEO Mike McMullen. "As we look ahead to 2024, we anticipate a slow but steady recovery. We have high confidence in the markets in which we have invested, the strength and resilience of our team, and the benefits of our build and buy growth strategy. Agilent is well-positioned for long-term growth."Agilent's financial performance in the fourth quarter and full fiscal year 2023 reflects the company's resilience in a challenging market. While certain segments experienced declines, others showed growth, and the company's overall financial health remains robust. Investors and stakeholders can look forward to a cautious but optimistic outlook for the coming fiscal year.Explore the complete 8-K earnings release (here) from Agilent Technologies Inc for further details.This article first appeared on GuruFocus."
Output: | 1,003 | true | 121.459999 | 123.919998 | 123.989998 | 126.620003 | 125.010002 | 124.709999 | UP | UP | UP | UP | UP | 1 | 1 | 1 | 1 | 1 | TRUE | 1 |
A | Agilent Technologies (A) closed at $127.63 in the latest trading session, marking a -0.56% move from the prior day. This change was narrower than the S&P 500's daily loss of 0.7%. Meanwhile, the Dow lost 0.54%, and the Nasdaq, a tech-heavy index, lost 1.17%.Coming into today, shares of the scientific instrument maker had gained 8.33% in the past month. In that same time, the Computer and Technology sector gained 1.4%, while the S&P 500 gained 2.35%.Investors will be hoping for strength from Agilent Technologies as it approaches its next earnings release, which is expected to be August 15, 2023. The company is expected to report EPS of $1.37, up 2.24% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $1.66 billion, down 3.56% from the prior-year quarter.For the full year, our Zacks Consensus Estimates are projecting earnings of $5.61 per share and revenue of $6.99 billion, which would represent changes of +7.47% and +2.07%, respectively, from the prior year.It is also important to note the recent changes to analyst estimates for Agilent Technologies. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.05% lower within the past month. Agilent Technologies is currently a Zacks Rank #3 (Hold).Digging into valuation, Agilent Technologies currently has a Forward P/E ratio of 22.87. This represents a discount compared to its industry's average Forward P/E of 25.76.Story continuesIt is also worth noting that A currently has a PEG ratio of 2.08. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Electronics - Testing Equipment stocks are, on average, holding a PEG ratio of 2.87 based on yesterday's closing prices.The Electronics - Testing Equipment industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 50, which puts it in the top 20% of all 250+ industries.The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | 2023-08-09T22:15:15 | Agilent Technologies (A) Stock Moves -0.56%: What You Should Know | https://finance.yahoo.com/news/agilent-technologies-stock-moves-0-221515546.html | 3af58521-aa5a-3ac4-8af8-4dd77e9ef858 | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "Agilent Technologies (A) closed at $127.63 in the latest trading session, marking a -0.56% move from the prior day. This change was narrower than the S&P 500's daily loss of 0.7%. Meanwhile, the Dow lost 0.54%, and the Nasdaq, a tech-heavy index, lost 1.17%.Coming into today, shares of the scientific instrument maker had gained 8.33% in the past month. In that same time, the Computer and Technology sector gained 1.4%, while the S&P 500 gained 2.35%.Investors will be hoping for strength from Agilent Technologies as it approaches its next earnings release, which is expected to be August 15, 2023. The company is expected to report EPS of $1.37, up 2.24% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $1.66 billion, down 3.56% from the prior-year quarter.For the full year, our Zacks Consensus Estimates are projecting earnings of $5.61 per share and revenue of $6.99 billion, which would represent changes of +7.47% and +2.07%, respectively, from the prior year.It is also important to note the recent changes to analyst estimates for Agilent Technologies. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.05% lower within the past month. Agilent Technologies is currently a Zacks Rank #3 (Hold).Digging into valuation, Agilent Technologies currently has a Forward P/E ratio of 22.87. This represents a discount compared to its industry's average Forward P/E of 25.76.Story continuesIt is also worth noting that A currently has a PEG ratio of 2.08. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Electronics - Testing Equipment stocks are, on average, holding a PEG ratio of 2.87 based on yesterday's closing prices.The Electronics - Testing Equipment industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 50, which puts it in the top 20% of all 250+ industries.The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research"
Output: | 788 | true | 128 | 127.650002 | 126.860001 | 126.650002 | 125.650002 | 121.360001 | DOWN | DOWN | DOWN | DOWN | DOWN | 0 | 0 | 0 | 0 | 0 | TRUE | 2 |
A | Technical University of Berlin researcher recognized for his innovative work in bioprocess engineeringSANTA CLARA, Calif., August 03, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced that Dr. Peter Neubauer has been selected to receive a prestigious Agilent Thought Leader Award. As Chair of Bioprocess Engineering at the Technical University of Berlin, Dr. Neubauer leads innovative research to identify new methods for more efficient bioprocess development, including genetic, cultivation, and analytical tools, with a particular focus on industrial-scale applications.Automation and high throughput are important for the real-time determination of critical quality attributes (CQAs), thus optimizing biotechnological applications. To this end, substantial resources are being directed toward developing process analytical technology (PAT) – a mechanism for designing, analyzing, and controlling pharmaceutical manufacturing processes by monitoring parameters that impact quality – to ultimately minimize public health risks.Dr. Neubauer’s work orchestrates hardware, software, automation, mathematical models, and AI to discover optimal conditions for PAT end-to-end workflows. Integrating intelligent technologies and automation into PAT solutions is a key factor for moving the pharmaceutical industry toward optimized bioprocesses that improve safety and reduce hands-on intervention. The Agilent Thought Leader Award will support his ongoing research into understanding and optimizing bioprocesses for difficult-to-express proteins and the development of scale-up/scale-down strategies."We are truly grateful and excited that Agilent's award will open up the opportunity to incorporate two-dimensional liquid chromatography and mass spectrometry into our upcoming bioprocess laboratory. The use of such leading-edge instrumentation is a fundamental element in our journey towards achieving a higher level in automated bioprocess development," said Dr. Neubauer who established and heads the KIWI-biolab as an International Future Laboratory for AI for Intelligent Integrated Biolaboratories. "Given our recent progress in seamlessly orchestrating all devices required in the process, ranging from extensive analyte-specific sample preparation to the management of big data, we feel ready to conquer this next logical step of integration."Story continues"Agilent is pleased to grant this Thought Leader Award to Dr. Neubauer to support his scientific developments in the biopharma space," said Sudharshana Seshadri, vice president and general manager of Agilent’s Liquid Chromatography, Mass Spectrometry, and Automation Divisions, and executive sponsor of the award. "His important work will help the pharmaceutical industry optimize their bioprocesses and accelerate improved healthcare worldwide."The Agilent Thought Leader Award program promotes fundamental scientific advances by contributing financial support, products, and expertise to the research of influential thought leaders in the life sciences, diagnostics, and chemical analysis space. To learn more, visit the Agilent Thought Leader Award website.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230803578963/en/ContactsMEDIA CONTACTNaomi GoumilloutAgilent Technologies+1.978.314.1862naomi.goumillout@agilent.com | Business Wire | 2023-08-03T12:00:00 | Agilent Announces Thought Leader Award to Peter Neubauer | https://finance.yahoo.com/news/agilent-announces-thought-leader-award-120000858.html | b63a32f6-fed1-3073-8709-daf31b435fc3 | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "Technical University of Berlin researcher recognized for his innovative work in bioprocess engineeringSANTA CLARA, Calif., August 03, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced that Dr. Peter Neubauer has been selected to receive a prestigious Agilent Thought Leader Award. As Chair of Bioprocess Engineering at the Technical University of Berlin, Dr. Neubauer leads innovative research to identify new methods for more efficient bioprocess development, including genetic, cultivation, and analytical tools, with a particular focus on industrial-scale applications.Automation and high throughput are important for the real-time determination of critical quality attributes (CQAs), thus optimizing biotechnological applications. To this end, substantial resources are being directed toward developing process analytical technology (PAT) – a mechanism for designing, analyzing, and controlling pharmaceutical manufacturing processes by monitoring parameters that impact quality – to ultimately minimize public health risks.Dr. Neubauer’s work orchestrates hardware, software, automation, mathematical models, and AI to discover optimal conditions for PAT end-to-end workflows. Integrating intelligent technologies and automation into PAT solutions is a key factor for moving the pharmaceutical industry toward optimized bioprocesses that improve safety and reduce hands-on intervention. The Agilent Thought Leader Award will support his ongoing research into understanding and optimizing bioprocesses for difficult-to-express proteins and the development of scale-up/scale-down strategies."We are truly grateful and excited that Agilent's award will open up the opportunity to incorporate two-dimensional liquid chromatography and mass spectrometry into our upcoming bioprocess laboratory. The use of such leading-edge instrumentation is a fundamental element in our journey towards achieving a higher level in automated bioprocess development," said Dr. Neubauer who established and heads the KIWI-biolab as an International Future Laboratory for AI for Intelligent Integrated Biolaboratories. "Given our recent progress in seamlessly orchestrating all devices required in the process, ranging from extensive analyte-specific sample preparation to the management of big data, we feel ready to conquer this next logical step of integration."Story continues"Agilent is pleased to grant this Thought Leader Award to Dr. Neubauer to support his scientific developments in the biopharma space," said Sudharshana Seshadri, vice president and general manager of Agilent’s Liquid Chromatography, Mass Spectrometry, and Automation Divisions, and executive sponsor of the award. "His important work will help the pharmaceutical industry optimize their bioprocesses and accelerate improved healthcare worldwide."The Agilent Thought Leader Award program promotes fundamental scientific advances by contributing financial support, products, and expertise to the research of influential thought leaders in the life sciences, diagnostics, and chemical analysis space. To learn more, visit the Agilent Thought Leader Award website.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230803578963/en/ContactsMEDIA CONTACTNaomi GoumilloutAgilent Technologies+1.978.314.1862naomi.goumillout@agilent.com "
Output: | 859 | true | 125.440002 | 126.300003 | 126.510002 | 128.350006 | 127.629997 | 127.650002 | UP | UP | UP | UP | UP | 1 | 1 | 1 | 1 | 1 | TRUE | 3 |
A | Cognex Corporation (CGNX) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 28%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.13, delivering a surprise of 44.44%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Cognex Corporation , which belongs to the Zacks Electronics - Testing Equipment industry, posted revenues of $242.51 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 4.99%. This compares to year-ago revenues of $274.63 million. The company has topped consensus revenue estimates three times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Cognex Corporation shares have added about 8.3% since the beginning of the year versus the S&P 500's gain of 17.6%.What's Next for Cognex Corporation?While Cognex Corporation has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Story continuesAhead of this earnings release, the estimate revisions trend for Cognex Corporation: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.29 on $248.76 million in revenues for the coming quarter and $0.95 on $934.45 million in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Electronics - Testing Equipment is currently in the top 23% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.One other stock from the same industry, Agilent Technologies (A), is yet to report results for the quarter ended July 2023. The results are expected to be released on August 15.This scientific instrument maker is expected to post quarterly earnings of $1.37 per share in its upcoming report, which represents a year-over-year change of +2.2%. The consensus EPS estimate for the quarter has been revised 0.2% lower over the last 30 days to the current level.Agilent Technologies' revenues are expected to be $1.66 billion, down 3.6% from the year-ago quarter.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCognex Corporation (CGNX) : Free Stock Analysis ReportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | 2023-08-03T11:25:15 | Cognex Corporation (CGNX) Beats Q2 Earnings and Revenue Estimates | https://finance.yahoo.com/news/cognex-corporation-cgnx-beats-q2-112515938.html | b015f3df-9c5c-30ea-bc1a-f1b841d1f79d | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "Cognex Corporation (CGNX) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 28%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.13, delivering a surprise of 44.44%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Cognex Corporation , which belongs to the Zacks Electronics - Testing Equipment industry, posted revenues of $242.51 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 4.99%. This compares to year-ago revenues of $274.63 million. The company has topped consensus revenue estimates three times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Cognex Corporation shares have added about 8.3% since the beginning of the year versus the S&P 500's gain of 17.6%.What's Next for Cognex Corporation?While Cognex Corporation has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Story continuesAhead of this earnings release, the estimate revisions trend for Cognex Corporation: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.29 on $248.76 million in revenues for the coming quarter and $0.95 on $934.45 million in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Electronics - Testing Equipment is currently in the top 23% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.One other stock from the same industry, Agilent Technologies (A), is yet to report results for the quarter ended July 2023. The results are expected to be released on August 15.This scientific instrument maker is expected to post quarterly earnings of $1.37 per share in its upcoming report, which represents a year-over-year change of +2.2%. The consensus EPS estimate for the quarter has been revised 0.2% lower over the last 30 days to the current level.Agilent Technologies' revenues are expected to be $1.66 billion, down 3.6% from the year-ago quarter.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCognex Corporation (CGNX) : Free Stock Analysis ReportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research"
Output: | 924 | true | 125.440002 | 126.300003 | 126.510002 | 128.350006 | 127.629997 | 127.650002 | UP | UP | UP | UP | UP | 1 | 1 | 1 | 1 | 1 | FALSE | 4 |
A | Employees once again rate the company as a top workplaceSANTA CLARA, Calif., July 10, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company has achieved certification as a Great Place to Work®. The recognition reflects Agilent's commitment to creating a positive work environment that fosters employee engagement, innovation, teamwork and professional growth.Agilent earned Great Place to Work certification in Australia, Austria, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Hong Kong, India, Ireland, Italy, Japan, Malaysia, Mexico, Netherlands, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, the United Kingdom, and the United States.The Great Place to Work certification is awarded to companies that meet the highest standards of organizational culture and employee satisfaction. It is based on a survey of Agilent’s workforce administered by the Great Place to Work Institute, which assesses employee satisfaction in key areas, from credibility and respect to fairness and camaraderie."We are thrilled to be certified as a Great Place to Work," said Mike McMullen, president and CEO of Agilent Technologies. "This achievement is a testament to the exceptional efforts of our 18,000 employees who contribute to our collaborative and welcoming workplace. At Agilent, we believe that a strong culture is essential to driving innovation and delivering superior solutions to our customers."Employees rated Agilent equal to or higher than the world’s Top 25 best workplaces on a variety of key areas, with 89 percent agreeing the company is a great place to work.The Great Place to Work certification adds to other workplace accolades Agilent has received this year, including U.S. News and World Report’s Best Companies for Work-Life Balance and Newsweek’s Greatest Workplaces. Learn more about Agilent’s culture, people and careers at careers.agilent.com.Story continuesAbout Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230707274953/en/ContactsMEDIA CONTACT: Sarah Litton+1 669 255 7696sarah.litton@agilent.com | Business Wire | 2023-07-10T14:52:00 | Agilent Achieves Great Place to Work® Certification | https://finance.yahoo.com/news/agilent-achieves-great-place-certification-145200273.html | 9f984233-a70a-3dd1-9168-5b05311228a4 | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "Employees once again rate the company as a top workplaceSANTA CLARA, Calif., July 10, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company has achieved certification as a Great Place to Work®. The recognition reflects Agilent's commitment to creating a positive work environment that fosters employee engagement, innovation, teamwork and professional growth.Agilent earned Great Place to Work certification in Australia, Austria, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Hong Kong, India, Ireland, Italy, Japan, Malaysia, Mexico, Netherlands, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, the United Kingdom, and the United States.The Great Place to Work certification is awarded to companies that meet the highest standards of organizational culture and employee satisfaction. It is based on a survey of Agilent’s workforce administered by the Great Place to Work Institute, which assesses employee satisfaction in key areas, from credibility and respect to fairness and camaraderie."We are thrilled to be certified as a Great Place to Work," said Mike McMullen, president and CEO of Agilent Technologies. "This achievement is a testament to the exceptional efforts of our 18,000 employees who contribute to our collaborative and welcoming workplace. At Agilent, we believe that a strong culture is essential to driving innovation and delivering superior solutions to our customers."Employees rated Agilent equal to or higher than the world’s Top 25 best workplaces on a variety of key areas, with 89 percent agreeing the company is a great place to work.The Great Place to Work certification adds to other workplace accolades Agilent has received this year, including U.S. News and World Report’s Best Companies for Work-Life Balance and Newsweek’s Greatest Workplaces. Learn more about Agilent’s culture, people and careers at careers.agilent.com.Story continuesAbout Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230707274953/en/ContactsMEDIA CONTACT: Sarah Litton+1 669 255 7696sarah.litton@agilent.com"
Output: | 651 | true | 118.300003 | 118.480003 | 120 | 119.349998 | 119.75 | 118.25 | UP | UP | UP | UP | DOWN | 1 | 1 | 1 | 1 | 0 | TRUE | 5 |
A | New capabilities offer simplicity and walkup usability for multimode detectionSANTA CLARA, Calif., July 10, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of new Gen6 software for all Agilent BioTek detection instruments. Featuring a broad range of prebuilt experiment templates for common applications, the new software provides automated optimization tools and improved navigation through built-in data analysis functions.Modern laboratories house an array of sophisticated analytical instruments controlled by equally sophisticated – and often formidably complex – software. Straightforward instrument control interfaces that quickly and reliably connect users to essential results can significantly increase the speed and ease with which scientific research efforts move forward.The design of the Agilent BioTek Gen6 software facilitates ‘walkup’ convenience for all users, regardless of experience level. The software also features an intuitive user interface that enables complete control of BioTek microplate readers for absorbance, fluorescence, and luminescence measurements in a variety of microplates for both endpoint and kinetic assays. Reading parameters, plate layout, and data analysis definition are easily established through a step-by-step process for both quantitative and qualitative assays. Additionally, well data and analysis results can be exported automatically or fully customized to suit data reporting requirements."The new Gen6 software for Agilent BioTek microplate readers delivers an improved user experience," said Caleb Foster, associate vice president of marketing for Agilent's Cell Analysis Division. "Agilent continues to develop innovative new plate readers to support our customers’ needs, driven by extensive user feedback. Gen6 is next-generation software providing new and seasoned users with the tools required for existing and future applications."Story continuesGen6 software is standard on all new Agilent BioTek microplate readers; existing users of Gen5 software can purchase an upgrade to Gen6.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230710563471/en/ContactsMEDIA CONTACTNaomi GoumilloutAgilent Technologies+1.781.266.2819naomi.goumillout@agilent.com | Business Wire | 2023-07-10T12:01:00 | Agilent Announces Gen6 Software for BioTek Line of Microplate Readers | https://finance.yahoo.com/news/agilent-announces-gen6-software-biotek-120100341.html | bec42551-4f7d-3ef1-b8c5-dfac5d41451b | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "New capabilities offer simplicity and walkup usability for multimode detectionSANTA CLARA, Calif., July 10, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of new Gen6 software for all Agilent BioTek detection instruments. Featuring a broad range of prebuilt experiment templates for common applications, the new software provides automated optimization tools and improved navigation through built-in data analysis functions.Modern laboratories house an array of sophisticated analytical instruments controlled by equally sophisticated – and often formidably complex – software. Straightforward instrument control interfaces that quickly and reliably connect users to essential results can significantly increase the speed and ease with which scientific research efforts move forward.The design of the Agilent BioTek Gen6 software facilitates ‘walkup’ convenience for all users, regardless of experience level. The software also features an intuitive user interface that enables complete control of BioTek microplate readers for absorbance, fluorescence, and luminescence measurements in a variety of microplates for both endpoint and kinetic assays. Reading parameters, plate layout, and data analysis definition are easily established through a step-by-step process for both quantitative and qualitative assays. Additionally, well data and analysis results can be exported automatically or fully customized to suit data reporting requirements."The new Gen6 software for Agilent BioTek microplate readers delivers an improved user experience," said Caleb Foster, associate vice president of marketing for Agilent's Cell Analysis Division. "Agilent continues to develop innovative new plate readers to support our customers’ needs, driven by extensive user feedback. Gen6 is next-generation software providing new and seasoned users with the tools required for existing and future applications."Story continuesGen6 software is standard on all new Agilent BioTek microplate readers; existing users of Gen5 software can purchase an upgrade to Gen6.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230710563471/en/ContactsMEDIA CONTACTNaomi GoumilloutAgilent Technologies+1.781.266.2819naomi.goumillout@agilent.com"
Output: | 646 | true | 118.300003 | 118.480003 | 120 | 119.349998 | 119.75 | 118.25 | UP | UP | UP | UP | DOWN | 1 | 1 | 1 | 1 | 0 | TRUE | 6 |
A | Agilent Technologies (A) closed at $119.42 in the latest trading session, marking a +0.62% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.77%. At the same time, the Dow lost 0.65%, and the tech-heavy Nasdaq lost 2.23%.Coming into today, shares of the scientific instrument maker had lost 0.68% in the past month. In that same time, the Computer and Technology sector gained 6.75%, while the S&P 500 gained 4.66%.Wall Street will be looking for positivity from Agilent Technologies as it approaches its next earnings report date. In that report, analysts expect Agilent Technologies to post earnings of $1.37 per share. This would mark year-over-year growth of 2.24%. Our most recent consensus estimate is calling for quarterly revenue of $1.66 billion, down 3.5% from the year-ago period.A's full-year Zacks Consensus Estimates are calling for earnings of $5.61 per share and revenue of $6.99 billion. These results would represent year-over-year changes of +7.47% and +2.04%, respectively.Investors should also note any recent changes to analyst estimates for Agilent Technologies. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.15% lower. Agilent Technologies is currently a Zacks Rank #4 (Sell).Looking at its valuation, Agilent Technologies is holding a Forward P/E ratio of 21.14. This valuation marks a discount compared to its industry's average Forward P/E of 25.53.Story continuesWe can also see that A currently has a PEG ratio of 1.92. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. A's industry had an average PEG ratio of 2.78 as of yesterday's close.The Electronics - Testing Equipment industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 61, which puts it in the top 25% of all 250+ industries.The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.To follow An in the coming trading sessions, be sure to utilize Zacks.com.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | 2023-06-23T22:15:19 | Agilent Technologies (A) Gains As Market Dips: What You Should Know | https://finance.yahoo.com/news/agilent-technologies-gains-market-dips-221519990.html | b2ec615e-21f8-3d9b-86e2-8a2ee0cfeea6 | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "Agilent Technologies (A) closed at $119.42 in the latest trading session, marking a +0.62% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.77%. At the same time, the Dow lost 0.65%, and the tech-heavy Nasdaq lost 2.23%.Coming into today, shares of the scientific instrument maker had lost 0.68% in the past month. In that same time, the Computer and Technology sector gained 6.75%, while the S&P 500 gained 4.66%.Wall Street will be looking for positivity from Agilent Technologies as it approaches its next earnings report date. In that report, analysts expect Agilent Technologies to post earnings of $1.37 per share. This would mark year-over-year growth of 2.24%. Our most recent consensus estimate is calling for quarterly revenue of $1.66 billion, down 3.5% from the year-ago period.A's full-year Zacks Consensus Estimates are calling for earnings of $5.61 per share and revenue of $6.99 billion. These results would represent year-over-year changes of +7.47% and +2.04%, respectively.Investors should also note any recent changes to analyst estimates for Agilent Technologies. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.15% lower. Agilent Technologies is currently a Zacks Rank #4 (Sell).Looking at its valuation, Agilent Technologies is holding a Forward P/E ratio of 21.14. This valuation marks a discount compared to its industry's average Forward P/E of 25.53.Story continuesWe can also see that A currently has a PEG ratio of 1.92. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. A's industry had an average PEG ratio of 2.78 as of yesterday's close.The Electronics - Testing Equipment industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 61, which puts it in the top 25% of all 250+ industries.The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.To follow An in the coming trading sessions, be sure to utilize Zacks.com.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research"
Output: | 766 | true | 118.959999 | 118.370003 | 117.040001 | 116.370003 | 118.050003 | 120.25 | DOWN | DOWN | DOWN | DOWN | UP | 0 | 0 | 0 | 0 | 1 | TRUE | 7 |
A | A month has gone by since the last earnings report for Agilent Technologies (A). Shares have lost about 2.2% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Agilent due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.Agilent Q2 Earnings Match EstimatesAgilent Technologies reported second-quarter fiscal 2023 earnings of $1.27 per share, which came in line with the Zacks Consensus Estimate. The bottom line increased by 12.4% from the year-ago fiscal quarter’s level.Revenues of $1.72 billion surpassed the Zacks Consensus Estimate of $1.67 billion. The top line was up 6.8% on a reported basis and 9.5% on a core basis from the respective year-ago fiscal quarter’s levels.Top-line growth was driven by strong momentum across Food, Academia & Gov’t and Chemistry & Advanced Materials markets. A strong performance in China also contributed well.Segmental Top Line DetailsAgilent has three reporting segments, namely, Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG) and Diagnostics and Genomics Group (DGG).LSAG: The segment accounted for $968 million or 56% of its total revenues, up 8% on a reported basis and 10% on a core basis from the respective prior-year fiscal quarter’s levels. This was driven by strong performance in the Chemical & Advanced Materials, Food and Academic & Gov’t markets. Strength in LC and LCMS and lab consumables also aided results.ACG: Revenues from the segment were $387 million, accounting for 23% of total revenues. Also, the top line improved by 10% from the prior-year fiscal quarter’s reading on a reported basis and 13% on a core basis, driven by strength in services attached to new instrument installations as well as expanding service offerings for the existing instrument base.DGG: Revenues increased 1% from the prior-year fiscal quarter’s figure on a reported basis and 3% on a core basis to $362 million, accounting for the remaining 21% of total revenues. Segmental growth was attributed to strength in the NASD and pathology businesses. Also, solid momentum in companion diagnostics pharma services contributed well.Story continuesOperating ResultsFor the fiscal second quarter, gross margin in the LSAG segment expanded by 90 basis points (bps) to 59.9% from the prior-year fiscal quarter’s number. ACG’s gross margin contracted 10 bps to 47%. DGG’s gross margin contracted 420 bps from the year-ago fiscal quarter’s actuals to 51.8%.Research & development (R&D) costs were $126 million, up 9.6% from the prior-year fiscal quarter’s number. Selling, general & administrative (SG&A) expenses were $415 million, up 7.5% from the year-earlier fiscal quarter’s figure. As a percentage of revenues, R&D expenses expanded 10 bps year over year to 7.3%. Meanwhile, SG&A expenses expanded 20 bps year over year to 24.2%.Operating margin for the fiscal first quarter was 22.3%, which contracted 10 bps from the year-earlier fiscal quarter’s figure.Segment-wise, the operating margin for LSAG was up 180 bps from the year-earlier fiscal quarter’s level of 27.3%. ACG’s operating margin was 26.6%, up 200 bps from the year-ago fiscal quarter’s level. DGG segment’s operating margin contracted 530 bps to 20.2% from the year-ago fiscal quarter’s figure.Balance Sheet & Cash FlowAs of Apr 30, 2023, Agilent’s cash and cash equivalents were $1.18 billion, down from $1.25 billion on Jan 31, 2023.Accounts receivables were $1.4 billion at the end of second-quarter fiscal 2023, down from $1.5 billion at the end of first-quarter fiscal 2023.Long-term debt was $2.733 billion for the reported quarter, which remained flat as compared with the prior fiscal quarter.Agilent generated $398 million in cash from operations during the reported quarter, up from $296 million generated in the previous quarter.Further, it returned $151 million to shareholders, out of which dividend payments accounted for $66 million and share repurchases accounted for the remaining $85 million.GuidanceFor the fiscal third quarter of 2023, management expects revenues of $1.640-$1.675 billion, suggesting growth between 4.5% and 2.5% on a core basis from the year-ago fiscal quarter’s actuals.Non-GAAP earnings per share are expected to be $1.36-$1.38.For fiscal 2023, management lowered its revenue guidance from the band of $7.03-$7.1 billion to $6.93-7.03 billion, implying a growth of 1.2-2.7% on a reported basis and 3-4.5% on a core basis from the respective fiscal 2022 figures.Management also updated the guidance for fiscal 2023 non-GAAP earnings per share downward from $5.65-$5.70 to $5.60-$5.65.How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in fresh estimates.VGM ScoresAt this time, Agilent has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Agilent has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | 2023-06-22T15:30:16 | Agilent (A) Down 2.2% Since Last Earnings Report: Can It Rebound? | https://finance.yahoo.com/news/agilent-down-2-2-since-153016196.html | ae802d93-e908-3b47-a275-408cfcb562c5 | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "A month has gone by since the last earnings report for Agilent Technologies (A). Shares have lost about 2.2% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Agilent due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.Agilent Q2 Earnings Match EstimatesAgilent Technologies reported second-quarter fiscal 2023 earnings of $1.27 per share, which came in line with the Zacks Consensus Estimate. The bottom line increased by 12.4% from the year-ago fiscal quarter’s level.Revenues of $1.72 billion surpassed the Zacks Consensus Estimate of $1.67 billion. The top line was up 6.8% on a reported basis and 9.5% on a core basis from the respective year-ago fiscal quarter’s levels.Top-line growth was driven by strong momentum across Food, Academia & Gov’t and Chemistry & Advanced Materials markets. A strong performance in China also contributed well.Segmental Top Line DetailsAgilent has three reporting segments, namely, Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG) and Diagnostics and Genomics Group (DGG).LSAG: The segment accounted for $968 million or 56% of its total revenues, up 8% on a reported basis and 10% on a core basis from the respective prior-year fiscal quarter’s levels. This was driven by strong performance in the Chemical & Advanced Materials, Food and Academic & Gov’t markets. Strength in LC and LCMS and lab consumables also aided results.ACG: Revenues from the segment were $387 million, accounting for 23% of total revenues. Also, the top line improved by 10% from the prior-year fiscal quarter’s reading on a reported basis and 13% on a core basis, driven by strength in services attached to new instrument installations as well as expanding service offerings for the existing instrument base.DGG: Revenues increased 1% from the prior-year fiscal quarter’s figure on a reported basis and 3% on a core basis to $362 million, accounting for the remaining 21% of total revenues. Segmental growth was attributed to strength in the NASD and pathology businesses. Also, solid momentum in companion diagnostics pharma services contributed well.Story continuesOperating ResultsFor the fiscal second quarter, gross margin in the LSAG segment expanded by 90 basis points (bps) to 59.9% from the prior-year fiscal quarter’s number. ACG’s gross margin contracted 10 bps to 47%. DGG’s gross margin contracted 420 bps from the year-ago fiscal quarter’s actuals to 51.8%.Research & development (R&D) costs were $126 million, up 9.6% from the prior-year fiscal quarter’s number. Selling, general & administrative (SG&A) expenses were $415 million, up 7.5% from the year-earlier fiscal quarter’s figure. As a percentage of revenues, R&D expenses expanded 10 bps year over year to 7.3%. Meanwhile, SG&A expenses expanded 20 bps year over year to 24.2%.Operating margin for the fiscal first quarter was 22.3%, which contracted 10 bps from the year-earlier fiscal quarter’s figure.Segment-wise, the operating margin for LSAG was up 180 bps from the year-earlier fiscal quarter’s level of 27.3%. ACG’s operating margin was 26.6%, up 200 bps from the year-ago fiscal quarter’s level. DGG segment’s operating margin contracted 530 bps to 20.2% from the year-ago fiscal quarter’s figure.Balance Sheet & Cash FlowAs of Apr 30, 2023, Agilent’s cash and cash equivalents were $1.18 billion, down from $1.25 billion on Jan 31, 2023.Accounts receivables were $1.4 billion at the end of second-quarter fiscal 2023, down from $1.5 billion at the end of first-quarter fiscal 2023.Long-term debt was $2.733 billion for the reported quarter, which remained flat as compared with the prior fiscal quarter.Agilent generated $398 million in cash from operations during the reported quarter, up from $296 million generated in the previous quarter.Further, it returned $151 million to shareholders, out of which dividend payments accounted for $66 million and share repurchases accounted for the remaining $85 million.GuidanceFor the fiscal third quarter of 2023, management expects revenues of $1.640-$1.675 billion, suggesting growth between 4.5% and 2.5% on a core basis from the year-ago fiscal quarter’s actuals.Non-GAAP earnings per share are expected to be $1.36-$1.38.For fiscal 2023, management lowered its revenue guidance from the band of $7.03-$7.1 billion to $6.93-7.03 billion, implying a growth of 1.2-2.7% on a reported basis and 3-4.5% on a core basis from the respective fiscal 2022 figures.Management also updated the guidance for fiscal 2023 non-GAAP earnings per share downward from $5.65-$5.70 to $5.60-$5.65.How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in fresh estimates.VGM ScoresAt this time, Agilent has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Agilent has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research"
Output: | 1,490 | true | 117.760002 | 119.419998 | 118.370003 | 117.040001 | 116.370003 | 118.050003 | UP | UP | DOWN | DOWN | UP | 1 | 1 | 0 | 0 | 1 | FALSE | 8 |
A | Agilent Technologies A is constantly gaining traction in molecular analyses on the back of its strength in liquid chromatography mass spectrometry (LCMS) offerings.This is evident from its latest InfinityLab Gel Permeation Chromatography/Size Exclusion Chromatography (GPC/SEC) solutions, which the company is gearing up to showcase at the HPLC 2023 conference.With the new solutions, which are designed for advanced material characterization, the company strengthened its Agilent InfinityLab GPC/SEC portfolio. Moreover, the portfolio now includes the benefits of the Polymer Standard Service acquisition.Notably, the new additions include the likes GPC/SEC column thermostat, the GPC/SEC-Ready Kit, a multi-angle light scattering detector and the powerful WinGPC Software.The combined portfolio of InfinityLab GPC/SEC and Polymer Standard Service will help Agilent cater well to the needs of scientists in macromolecular analysis.Also, it will aid its momentum across the chemical, food, pharmaceutical and biopharmaceutical industries.Agilent Technologies, Inc. Price and ConsensusAgilent Technologies, Inc. Price and ConsensusAgilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. QuoteLSAG Segment in FocusThe latest move bodes well for the company’s growing efforts toward bolstering its Life Sciences & Applied Markets Group (LSAG) segment, which contributes the most to total revenues.Apart from the expansion of the Agilent InfinityLab GPC/SEC portfolio, the company recently launched the 6495 Triple Quadrupole LC/MS (LC/TQ) System and the Revident Quadrupole Time-of-Flight LC/MS (LC/QTOF) System.Notably, 6495 LC/TQ is designed to take care of the critical transition between the discovery phase of research and the translational phase to generate meaningful scientific insights on the back of its intelligence features.Meanwhile, Revident LC/Q-TOF features instrument intelligence for maximized operation time and productivity and a novel detection system that boosts spectral purity.Story continuesTo ConcludeThe abovementioned endeavors are expected to continue aiding the performance of the LSAG segment.In second-quarter fiscal 2023, the underlined segment generated $968 million in revenues, which accounted for 56% of the total revenues. The figure was up 8% on a reported basis and 10% on a core basis from the prior-year fiscal quarter’s levels.We believe the company’s strong focus on bolstering the LSAG segment will benefit its overall performance.For fiscal 2023, Agilent expects revenues between $6.93 billion and $7.03 billion, implying growth of 1.2-2.7% on a reported basis and 3-4.5% on a core basis from the respective fiscal 2022 figures. The Zacks Consensus Estimate for Agilent's fiscal 2023 revenues is pegged at $6.99 billion, indicating growth of 2% from 2022.However, mounting expenses do not bode well for the company’s profitability. Further, macroeconomic headwinds and uncertainties in the demand environment remain concerns.Coming to price performance, Agilent has lost 20% in the year-to-date period against the industry’s growth of 4.5%.Zacks Rank & Stocks to ConsiderCurrently, Agilent Technologies carries a Zacks Rank #4 (Sell).Some better-ranked stocks in the broader technology sector are Palo Alto Networks PANW, NVIDIA NVDA and AMETEK AME. While Palo Alto Networks and NVIDIA sport a Zacks Rank #1 (Strong Buy) each, AME carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Palo Alto Networks shares have gained 65% in the year-to-date period. The long-term earnings growth rate for PANW is currently projected at 31.5%.NVIDIA shares rallied 173.8% in the year-to-date period. Its long-term earnings growth rate is presently projected at 23.02%.AMETEK shares have increased by 10.2% in the year-to-date period. The long-term earnings growth rate for AME is currently projected at 8.95%.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportNVIDIA Corporation (NVDA) : Free Stock Analysis ReportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportAMETEK, Inc. (AME) : Free Stock Analysis ReportPalo Alto Networks, Inc. (PANW) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | 2023-06-14T15:54:00 | Agilent (A) Boosts LSAG Segment With New GPC/SEC Solutions | https://finance.yahoo.com/news/agilent-boosts-lsag-segment-gpc-155400344.html | 12e219cf-9283-33d7-a609-0a826aba7397 | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "Agilent Technologies A is constantly gaining traction in molecular analyses on the back of its strength in liquid chromatography mass spectrometry (LCMS) offerings.This is evident from its latest InfinityLab Gel Permeation Chromatography/Size Exclusion Chromatography (GPC/SEC) solutions, which the company is gearing up to showcase at the HPLC 2023 conference.With the new solutions, which are designed for advanced material characterization, the company strengthened its Agilent InfinityLab GPC/SEC portfolio. Moreover, the portfolio now includes the benefits of the Polymer Standard Service acquisition.Notably, the new additions include the likes GPC/SEC column thermostat, the GPC/SEC-Ready Kit, a multi-angle light scattering detector and the powerful WinGPC Software.The combined portfolio of InfinityLab GPC/SEC and Polymer Standard Service will help Agilent cater well to the needs of scientists in macromolecular analysis.Also, it will aid its momentum across the chemical, food, pharmaceutical and biopharmaceutical industries.Agilent Technologies, Inc. Price and ConsensusAgilent Technologies, Inc. Price and ConsensusAgilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. QuoteLSAG Segment in FocusThe latest move bodes well for the company’s growing efforts toward bolstering its Life Sciences & Applied Markets Group (LSAG) segment, which contributes the most to total revenues.Apart from the expansion of the Agilent InfinityLab GPC/SEC portfolio, the company recently launched the 6495 Triple Quadrupole LC/MS (LC/TQ) System and the Revident Quadrupole Time-of-Flight LC/MS (LC/QTOF) System.Notably, 6495 LC/TQ is designed to take care of the critical transition between the discovery phase of research and the translational phase to generate meaningful scientific insights on the back of its intelligence features.Meanwhile, Revident LC/Q-TOF features instrument intelligence for maximized operation time and productivity and a novel detection system that boosts spectral purity.Story continuesTo ConcludeThe abovementioned endeavors are expected to continue aiding the performance of the LSAG segment.In second-quarter fiscal 2023, the underlined segment generated $968 million in revenues, which accounted for 56% of the total revenues. The figure was up 8% on a reported basis and 10% on a core basis from the prior-year fiscal quarter’s levels.We believe the company’s strong focus on bolstering the LSAG segment will benefit its overall performance.For fiscal 2023, Agilent expects revenues between $6.93 billion and $7.03 billion, implying growth of 1.2-2.7% on a reported basis and 3-4.5% on a core basis from the respective fiscal 2022 figures. The Zacks Consensus Estimate for Agilent's fiscal 2023 revenues is pegged at $6.99 billion, indicating growth of 2% from 2022.However, mounting expenses do not bode well for the company’s profitability. Further, macroeconomic headwinds and uncertainties in the demand environment remain concerns.Coming to price performance, Agilent has lost 20% in the year-to-date period against the industry’s growth of 4.5%.Zacks Rank & Stocks to ConsiderCurrently, Agilent Technologies carries a Zacks Rank #4 (Sell).Some better-ranked stocks in the broader technology sector are Palo Alto Networks PANW, NVIDIA NVDA and AMETEK AME. While Palo Alto Networks and NVIDIA sport a Zacks Rank #1 (Strong Buy) each, AME carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Palo Alto Networks shares have gained 65% in the year-to-date period. The long-term earnings growth rate for PANW is currently projected at 31.5%.NVIDIA shares rallied 173.8% in the year-to-date period. Its long-term earnings growth rate is presently projected at 23.02%.AMETEK shares have increased by 10.2% in the year-to-date period. The long-term earnings growth rate for AME is currently projected at 8.95%.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportNVIDIA Corporation (NVDA) : Free Stock Analysis ReportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportAMETEK, Inc. (AME) : Free Stock Analysis ReportPalo Alto Networks, Inc. (PANW) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research"
Output: | 1,059 | true | 118.879997 | 121.230003 | 121.129997 | 118.160004 | 118.330002 | 118.68 | UP | UP | DOWN | DOWN | DOWN | 1 | 1 | 0 | 0 | 0 | TRUE | 9 |
A | Baron Funds, an investment management firm, released its "Baron Durable Advantage Fund" first quarter 2023 investor letter, a copy of which can be downloaded here. The Baron Durable Advantage Fund gained 16.0% during the first quarter, compared favorably to its S&P 500 benchmark which earned a 7.5% return for the same period. Spare some time to check the fund’s top 5 holdings to know more about their top bets for 2023.In its Q1 2023 investor letter, Baron Durable Advantage Fund mentioned Agilent Technologies Inc. (NYSE:A) and explained its insights for the company. Founded in 1999, Agilent Technologies Inc. (NYSE:A) is a Santa Clara, California-based research and testing company with a $35.2 billion market capitalization. Agilent Technologies Inc. (NYSE:A) delivered a -20.35% return since the beginning of the year, while its 12-month returns are up by 2.75%. The stock closed at $118.54 per share on June 12, 2023.Here is what Baron Durable Advantage Fund has to say about Agilent Technologies Inc. (NYSE:A) in its Q1 2023 investor letter:"Agilent Technologies, Inc. (A) provides instruments, software, services, and consumables for the life sciences, diagnostics, and applied chemicals markets. Despite reporting solid financial results with 10% year-over-year core revenue growth and 13% EPS growth, shares declined 7.6% during the first quarter on investor anticipation of a tougher macro environment later in 2023. We continue to believe Agilent is well positioned for long-term durable growth, driven by innovation, new product development, and its end market and geographic mix. Over time, Agilent will benefit from a shift in its business mix to higher-growth pharmaceutical, diagnostics, and research markets, while its leading competitive positioning and scale should enable it to raise margins over time."Our calculations show that Agilent Technologies Inc. (NYSE:A) was not able to secure a spot on our list of the 30 Most Popular Stocks Among Hedge Funds. Agilent Technologies Inc. (NYSE:A) was in 55 hedge fund portfolios at the end of the first quarter of 2023, compared to 48 funds in the previous quarter. Agilent Technologies Inc. (NYSE:A) delivered a -13.87% return in the past 3 months.Story continuesOn January this year, we also shared another hedge fund’s views on Agilent Technologies Inc. (NYSE:A) in another article. You can find other investor letters from hedge funds and prominent investors on our hedge fund investor letters Q1 2023 page. Suggested Articles:25 Countries With The Highest Cost of Living In The World in 202320 Best Countries to Retire Overseas Where English is Spoken12 Best Energy Stocks To Invest In According to AnalystsDisclosure: None. This article is originally published at Insider Monkey. | Insider Monkey | 2023-06-13T16:02:51 | Is it a Good Time to Invest in Agilent (A) Shares? | https://finance.yahoo.com/news/auto-draft-160255368.html | 60bfb7fa-9248-3d17-b654-6b18858a4e5c | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "Baron Funds, an investment management firm, released its "Baron Durable Advantage Fund" first quarter 2023 investor letter, a copy of which can be downloaded here. The Baron Durable Advantage Fund gained 16.0% during the first quarter, compared favorably to its S&P 500 benchmark which earned a 7.5% return for the same period. Spare some time to check the fund’s top 5 holdings to know more about their top bets for 2023.In its Q1 2023 investor letter, Baron Durable Advantage Fund mentioned Agilent Technologies Inc. (NYSE:A) and explained its insights for the company. Founded in 1999, Agilent Technologies Inc. (NYSE:A) is a Santa Clara, California-based research and testing company with a $35.2 billion market capitalization. Agilent Technologies Inc. (NYSE:A) delivered a -20.35% return since the beginning of the year, while its 12-month returns are up by 2.75%. The stock closed at $118.54 per share on June 12, 2023.Here is what Baron Durable Advantage Fund has to say about Agilent Technologies Inc. (NYSE:A) in its Q1 2023 investor letter:"Agilent Technologies, Inc. (A) provides instruments, software, services, and consumables for the life sciences, diagnostics, and applied chemicals markets. Despite reporting solid financial results with 10% year-over-year core revenue growth and 13% EPS growth, shares declined 7.6% during the first quarter on investor anticipation of a tougher macro environment later in 2023. We continue to believe Agilent is well positioned for long-term durable growth, driven by innovation, new product development, and its end market and geographic mix. Over time, Agilent will benefit from a shift in its business mix to higher-growth pharmaceutical, diagnostics, and research markets, while its leading competitive positioning and scale should enable it to raise margins over time."Our calculations show that Agilent Technologies Inc. (NYSE:A) was not able to secure a spot on our list of the 30 Most Popular Stocks Among Hedge Funds. Agilent Technologies Inc. (NYSE:A) was in 55 hedge fund portfolios at the end of the first quarter of 2023, compared to 48 funds in the previous quarter. Agilent Technologies Inc. (NYSE:A) delivered a -13.87% return in the past 3 months.Story continuesOn January this year, we also shared another hedge fund’s views on Agilent Technologies Inc. (NYSE:A) in another article. You can find other investor letters from hedge funds and prominent investors on our hedge fund investor letters Q1 2023 page. Suggested Articles:25 Countries With The Highest Cost of Living In The World in 202320 Best Countries to Retire Overseas Where English is Spoken12 Best Energy Stocks To Invest In According to AnalystsDisclosure: None. This article is originally published at Insider Monkey."
Output: | 683 | true | 119.989998 | 119.400002 | 121.230003 | 121.129997 | 118.160004 | 118.330002 | DOWN | UP | UP | DOWN | DOWN | 0 | 1 | 1 | 0 | 0 | TRUE | 10 |
A | Integration of Polymer Standards Service Ltd. products results in the most complete and versatile GPC/SEC portfolio on the marketSANTA CLARA, Calif., June 12, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced they will showcase their significantly expanded InfinityLab GPC/SEC Solution at the HPLC 2023 conference on June 18 – 22, 2023 in Düsseldorf, Germany.The Agilent InfinityLab GPC/SEC portfolio has become even more comprehensive as it incorporates added value components from recent acquisition of Polymer Standard Service Ltd. (PSS) including a dedicated GPC/SEC Column Thermostat, a Multi-Angle Light Scattering Detector, the GPC/SEC-Ready Kit, and the powerful WinGPC Software into the already existing InfinityLab GPC/SEC Solutions for advanced material characterization.In combination with Agilent GPC/SEC products like the Bio-GPC/SEC system, High-Temperature GPC system, routine-GPC/SEC software, GPC/SEC columns, standards, and dedicated service offerings this launch of additional products results in the largest one-vendor solution for GPC/SEC."We are so pleased to unveil the new GPC/SEC solutions at HPLC," said Sudharshana Seshadri, vice president of Agilent’s Liquid Chromatography, Mass Spec and Automation divisions. "The combined portfolio of Agilent and PSS delivers a total Agilent solution for the characterization of macromolecules. It enables scientists to update legacy methods, to improve productivity or to address the challenges of characterizing new and innovative high-performance materials for applications within the food, pharmaceutical and biotechnology industries.""Our goal at Agilent," continued Sudharshana Seshadri, "is to deliver the best solutions we can for our customers, considering their current and future needs. Having PSS on board brings unique expertise in serving macromolecular analysis, and combining that with Agilent’s knowledge, and strengths, enables us to address the emerging challenges that customers are facing."Story continuesAlso on display, for the first time in Europe at the HPLC 2023 conference, on the Agilent booth #3 will be: 1260 Infinity II Hybrid Multisampler offering unique capabilities for complex samples; the 1290 Infinity II Bio Online Sample Manager which together with the 1290 Infinity II LC systems, creates a high-end PAT-solution, and the Revident Quadrupole Time-of-Flight LC/MS (LC/Q-TOF) System.Agilent’s second booth #4 will showcase Agilent’s digital lab solutions. Lab optimization strategies will be articulated around key solutions such as efficient data management systems, electronic laboratory notebooks, scientific asset performance management and digital tools designed to track inventories, manage schedules, aggregate data, provide resource visibility, monitor asset performance & utilization, and integrate with other lab systems.GPC/SECGel Permeation Chromatography / Size Exclusion Chromatography (GPC/SEC) is an important separation technique for synthetic and natural polymers. GPC/SEC analysis is widely used in the chemical-, food-, pharmaceutical- and biopharmaceutical industry and research in applications to determine the molecular weight and size distribution of macromolecules.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230612005069/en/ContactsCatherine KayeAgilent Technologies+44 (0) 7775 410632Catherine.kaye@agilent.com | Business Wire | 2023-06-12T12:00:00 | Agilent Introduces New Comprehensive GPC/SEC Solutions at HPLC 2023 Conference | https://finance.yahoo.com/news/agilent-introduces-comprehensive-gpc-sec-120000312.html | e2e9e23d-c964-3280-979d-52f269bf8ffd | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "Integration of Polymer Standards Service Ltd. products results in the most complete and versatile GPC/SEC portfolio on the marketSANTA CLARA, Calif., June 12, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced they will showcase their significantly expanded InfinityLab GPC/SEC Solution at the HPLC 2023 conference on June 18 – 22, 2023 in Düsseldorf, Germany.The Agilent InfinityLab GPC/SEC portfolio has become even more comprehensive as it incorporates added value components from recent acquisition of Polymer Standard Service Ltd. (PSS) including a dedicated GPC/SEC Column Thermostat, a Multi-Angle Light Scattering Detector, the GPC/SEC-Ready Kit, and the powerful WinGPC Software into the already existing InfinityLab GPC/SEC Solutions for advanced material characterization.In combination with Agilent GPC/SEC products like the Bio-GPC/SEC system, High-Temperature GPC system, routine-GPC/SEC software, GPC/SEC columns, standards, and dedicated service offerings this launch of additional products results in the largest one-vendor solution for GPC/SEC."We are so pleased to unveil the new GPC/SEC solutions at HPLC," said Sudharshana Seshadri, vice president of Agilent’s Liquid Chromatography, Mass Spec and Automation divisions. "The combined portfolio of Agilent and PSS delivers a total Agilent solution for the characterization of macromolecules. It enables scientists to update legacy methods, to improve productivity or to address the challenges of characterizing new and innovative high-performance materials for applications within the food, pharmaceutical and biotechnology industries.""Our goal at Agilent," continued Sudharshana Seshadri, "is to deliver the best solutions we can for our customers, considering their current and future needs. Having PSS on board brings unique expertise in serving macromolecular analysis, and combining that with Agilent’s knowledge, and strengths, enables us to address the emerging challenges that customers are facing."Story continuesAlso on display, for the first time in Europe at the HPLC 2023 conference, on the Agilent booth #3 will be: 1260 Infinity II Hybrid Multisampler offering unique capabilities for complex samples; the 1290 Infinity II Bio Online Sample Manager which together with the 1290 Infinity II LC systems, creates a high-end PAT-solution, and the Revident Quadrupole Time-of-Flight LC/MS (LC/Q-TOF) System.Agilent’s second booth #4 will showcase Agilent’s digital lab solutions. Lab optimization strategies will be articulated around key solutions such as efficient data management systems, electronic laboratory notebooks, scientific asset performance management and digital tools designed to track inventories, manage schedules, aggregate data, provide resource visibility, monitor asset performance & utilization, and integrate with other lab systems.GPC/SECGel Permeation Chromatography / Size Exclusion Chromatography (GPC/SEC) is an important separation technique for synthetic and natural polymers. GPC/SEC analysis is widely used in the chemical-, food-, pharmaceutical- and biopharmaceutical industry and research in applications to determine the molecular weight and size distribution of macromolecules.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230612005069/en/ContactsCatherine KayeAgilent Technologies+44 (0) 7775 410632Catherine.kaye@agilent.com"
Output: | 951 | true | 118.68 | 119.5 | 119.400002 | 121.230003 | 121.129997 | 118.160004 | UP | UP | UP | UP | DOWN | 1 | 1 | 1 | 1 | 0 | TRUE | 11 |
A | UCLA scientist recognized for research developing live cell analytical tools to advance bioprocess and biomanufacturing applicationsSANTA CLARA, Calif., August 09, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that Ajit Divakaruni, Ph.D., has received the Agilent 2023 Early Career Professor Award. Dr. Divakaruni is an Assistant Professor in the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA).The 2023 award focused on contributions to developing live cell analytical tools to identify and measure novel critical quality attributes to advance biomanufacturing applications. Dr. Divakaruni’s interest in developing cell-based metabolic assays to guide CAR-T cell manufacturing and bioprocess development strongly aligns with Agilent’s increasing attention to developing solutions that support immunotherapies and other cell-based therapies.The Divakaruni lab focuses on how energy metabolism and metabolic flexibility – the ability to switch between sugar, amino acid, and fatty acid oxidation in response to biological cues – can control cell function and fate. This research aims to discover novel regulatory points of metabolism and develop mitochondrial proteins and pathways as therapeutic drug targets."I am honored and beyond grateful to have been selected as this year’s recipient of the Agilent Early Career Professor Award. It is a privilege to be recognized for our work in developing mitochondrial and metabolic assays to help guide early-stage drug development and inform cell-based therapeutics," said Dr. Divakaruni. "Real-time, microplate-based assays have been central to the resurgent interest in cellular metabolism, and these will continue to be at the forefront as we continue to learn even more about how mitochondria and metabolism can shape cell function.""Dr. Divakaruni’s innovative research is expanding the basic science of understanding how cell metabolism can be a driver of cell function and fate and has also made critical contributions to live cell measurement tools that elevate researchers in this field," said Chong Wing Yung, associate director of University Relations and External Research at Agilent. "We are proud to further engage with Dr. Divakaruni and support his future research endeavors, including analytical technologies for bioprocess and biomanufacturing applications."Story continuesDr. Divakaruni’s current work includes studying the crosstalk between metabolism and innate immunity and examining how adjusting the balance between sugar, fat, and amino acid oxidation can affect metabolic and neurological disease. The development and refinement of functional mitochondrial measurements are central to this work, and the Divakaruni lab emphasizes protocols and ‘roadmap’ manuscripts that may assist other researchers as they plan their experiments.Future directions of Dr. Divakaruni’s research include developing novel cell-based metabolic assays to guide CAR-T cell bioprocess development and biomanufacturing. As critical quality attributes for producing efficacious cell therapies are still poorly defined, his expertise in cell metabolism and cell analysis will play a key role in helping to define these standards.The Agilent Early Career Professor Award is an annual program that recognizes and supports promising research from professors who, early in their careers, show outstanding potential for future research in areas of importance to the communities Agilent serves. This award underscores Agilent's commitment to furthering research through the company's products and services, financial support, and collaborative engagement by Agilent scientists and engineers. Further information about the program is available at Agilent.com.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230809371185/en/ContactsNaomi GoumilloutAgilent Technologies+1.978.314.1862naomi.goumillout@agilent.com | Business Wire | 2023-08-09T12:00:00 | Agilent 2023 Early Career Professor Award Presented to Ajit Divakaruni | https://finance.yahoo.com/news/agilent-2023-early-career-professor-120000771.html | cb3fb834-e666-3566-b8da-e48bc6339b60 | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "UCLA scientist recognized for research developing live cell analytical tools to advance bioprocess and biomanufacturing applicationsSANTA CLARA, Calif., August 09, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that Ajit Divakaruni, Ph.D., has received the Agilent 2023 Early Career Professor Award. Dr. Divakaruni is an Assistant Professor in the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA).The 2023 award focused on contributions to developing live cell analytical tools to identify and measure novel critical quality attributes to advance biomanufacturing applications. Dr. Divakaruni’s interest in developing cell-based metabolic assays to guide CAR-T cell manufacturing and bioprocess development strongly aligns with Agilent’s increasing attention to developing solutions that support immunotherapies and other cell-based therapies.The Divakaruni lab focuses on how energy metabolism and metabolic flexibility – the ability to switch between sugar, amino acid, and fatty acid oxidation in response to biological cues – can control cell function and fate. This research aims to discover novel regulatory points of metabolism and develop mitochondrial proteins and pathways as therapeutic drug targets."I am honored and beyond grateful to have been selected as this year’s recipient of the Agilent Early Career Professor Award. It is a privilege to be recognized for our work in developing mitochondrial and metabolic assays to help guide early-stage drug development and inform cell-based therapeutics," said Dr. Divakaruni. "Real-time, microplate-based assays have been central to the resurgent interest in cellular metabolism, and these will continue to be at the forefront as we continue to learn even more about how mitochondria and metabolism can shape cell function.""Dr. Divakaruni’s innovative research is expanding the basic science of understanding how cell metabolism can be a driver of cell function and fate and has also made critical contributions to live cell measurement tools that elevate researchers in this field," said Chong Wing Yung, associate director of University Relations and External Research at Agilent. "We are proud to further engage with Dr. Divakaruni and support his future research endeavors, including analytical technologies for bioprocess and biomanufacturing applications."Story continuesDr. Divakaruni’s current work includes studying the crosstalk between metabolism and innate immunity and examining how adjusting the balance between sugar, fat, and amino acid oxidation can affect metabolic and neurological disease. The development and refinement of functional mitochondrial measurements are central to this work, and the Divakaruni lab emphasizes protocols and ‘roadmap’ manuscripts that may assist other researchers as they plan their experiments.Future directions of Dr. Divakaruni’s research include developing novel cell-based metabolic assays to guide CAR-T cell bioprocess development and biomanufacturing. As critical quality attributes for producing efficacious cell therapies are still poorly defined, his expertise in cell metabolism and cell analysis will play a key role in helping to define these standards.The Agilent Early Career Professor Award is an annual program that recognizes and supports promising research from professors who, early in their careers, show outstanding potential for future research in areas of importance to the communities Agilent serves. This award underscores Agilent's commitment to furthering research through the company's products and services, financial support, and collaborative engagement by Agilent scientists and engineers. Further information about the program is available at Agilent.com.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230809371185/en/ContactsNaomi GoumilloutAgilent Technologies+1.978.314.1862naomi.goumillout@agilent.com"
Output: | 985 | true | 128 | 127.650002 | 126.860001 | 126.650002 | 125.650002 | 121.360001 | DOWN | DOWN | DOWN | DOWN | DOWN | 0 | 0 | 0 | 0 | 0 | TRUE | 12 |
A | SANTA CLARA, Calif., June 08, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of the Agilent BioTek 406 FX washer dispenser, a compact instrument that combines multifunctional reagent dispensing and plate-washing capabilities. The BioTek 406 FX offers expanded liquid handling features designed for integration into automated systems and standalone benchtop use.Key features of the new BioTek 406 FX improve upon the benefits of the first-generation EL406 and include:Secondary peristaltic and dual syringe pumps.A touchscreen interface.Enhanced flexibility for automated workflows across a broad range of applications, such as cell-based and magnetic bead-based assays.The additional reagent dispense pumps enable up to six different reagents to be dispensed using the pump technology best suited to each step of the workflow. Combining multiple assay workflow step capabilities in a single instrument is expected to be particularly beneficial for laboratories confronting space and budgetary constraints. The 406 FX plate carrier can be accessed from the right or left side, making it ideally suited for integration into robotic systems.Caleb Foster, associate vice president of marketing for Agilent's Cell Analysis Division, discussed the impact of the release. "The launch of the 406 FX is an exciting step in the evolution of the Agilent BioTek liquid handling product line – one that incorporates years of customer feedback received from the EL406," he said. "This flexible platform replaces several instruments in one, with market-leading multifunctional capabilities.""It's a true workhorse instrument that can be used for cell-based assays, ELISA, and many other microplate-based workflows, and it brings the flexibility and reliability customers have come to expect from our products," Foster added.BioTek microplate washer dispensers are used widely throughout the life sciences industry. They are an integral part of a suite of automation-friendly Agilent solutions that aim to improve throughput and ease of use in complex end-to-end cell analysis workflows.Story continuesAbout Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005192/en/ContactsNaomi GoumilloutAgilent Technologies Inc.+1.978.314.1862naomi.goumillout@agilent.com | Business Wire | 2023-06-08T12:00:00 | Agilent Announces BioTek 406 FX Washer Dispenser for Technology-Driven Workflow Efficiency | https://finance.yahoo.com/news/agilent-announces-biotek-406-fx-120000698.html | 7e697787-2da4-3e44-b539-4e69ec1fcb06 | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "SANTA CLARA, Calif., June 08, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of the Agilent BioTek 406 FX washer dispenser, a compact instrument that combines multifunctional reagent dispensing and plate-washing capabilities. The BioTek 406 FX offers expanded liquid handling features designed for integration into automated systems and standalone benchtop use.Key features of the new BioTek 406 FX improve upon the benefits of the first-generation EL406 and include:Secondary peristaltic and dual syringe pumps.A touchscreen interface.Enhanced flexibility for automated workflows across a broad range of applications, such as cell-based and magnetic bead-based assays.The additional reagent dispense pumps enable up to six different reagents to be dispensed using the pump technology best suited to each step of the workflow. Combining multiple assay workflow step capabilities in a single instrument is expected to be particularly beneficial for laboratories confronting space and budgetary constraints. The 406 FX plate carrier can be accessed from the right or left side, making it ideally suited for integration into robotic systems.Caleb Foster, associate vice president of marketing for Agilent's Cell Analysis Division, discussed the impact of the release. "The launch of the 406 FX is an exciting step in the evolution of the Agilent BioTek liquid handling product line – one that incorporates years of customer feedback received from the EL406," he said. "This flexible platform replaces several instruments in one, with market-leading multifunctional capabilities.""It's a true workhorse instrument that can be used for cell-based assays, ELISA, and many other microplate-based workflows, and it brings the flexibility and reliability customers have come to expect from our products," Foster added.BioTek microplate washer dispensers are used widely throughout the life sciences industry. They are an integral part of a suite of automation-friendly Agilent solutions that aim to improve throughput and ease of use in complex end-to-end cell analysis workflows.Story continuesAbout Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005192/en/ContactsNaomi GoumilloutAgilent Technologies Inc.+1.978.314.1862naomi.goumillout@agilent.com"
Output: | 686 | true | 115.580002 | 115.790001 | 118.540001 | 119.5 | 119.400002 | 121.230003 | UP | UP | UP | UP | UP | 1 | 1 | 1 | 1 | 1 | TRUE | 13 |
A | Labs seek guidance in reducing their environmental footprint by increasing efficiency but overall convey optimism on sustainability effortsSANTA CLARA, Calif., June 08, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the results of an independent third-party global survey that will help the industry better understand analytical laboratories’ perceptions, aspirations, and challenges concerning implementing sustainability measures.Conducted on behalf of Agilent by the international market research firm Frost & Sullivan, the survey sought to understand how lab managers globally are thinking about sustainability and reducing the environmental impact of their labs and how vendors like Agilent can help by improving products and services to address their needs and current gaps.The survey took a two-phased approach with 100 qualitative phone interviews, followed by 500 online interviews with experienced lab personnel in Asia, Europe, the United Kingdom, and the United States across all the lab types and market segments Agilent serves. The primary functions of the labs surveyed were analytical services, methods development or validation, process control, monitoring or manufacturing, quality assurance or control, research, and clinical testing.The results indicated that a high percentage (82%) of labs surveyed have already adopted sustainability measures. The top three actions that labs are currently undertaking to reduce their environmental footprint are: reducing carbon and other greenhouse gas emissions (72%), reducing or optimizing water and energy consumption (68%), and improving waste management techniques (60%). Also, 85% of those surveyed expect their vendors to support them in reaching their sustainability goals, now and in the future, and 74% of labs stated that it would be an exclusion criterion for them to engage with a company commercially that did not have a commitment to net zero."A majority of labs stated that information shared by vendors, related to their own goals and objectives towards sustainability, in addition to instrument and product-related information, was important," said Neil Rees, head of Agilent’s ESG Programs. "Our ongoing partnership with My Green Lab and their ACT Environmental Impact Factor Label program ensures that we can offer our customers third-party verified information on the environmental impact of Agilent solutions."Story continues"By providing the necessary verification and transparency of sustainability information, MGL ACT labels help consumers make informed decisions across the lifecycle impact of laboratory products," said James Connelly, My Green Lab CEO. "Participating in ACT is a key way manufacturers demonstrate their commitment to our mission to build a global culture of sustainability in science."Additionally, 54% of labs would be interested in consulting services to assess and improve lab efficiency, followed by instruments and systems that support tracking and monitoring key metrics related to sustainability (44%). Labs are also looking to vendors to provide instrument end-of-life solutions, for example, recycling services (77%) and instrument refurbishment initiatives (51%), such as Agilent’s Certified Pre-Owned Instruments Program. Agilent also showcased a selection of its MGL ACT-labelled products at the ASMS Conference held June 4 - 8 in Houston, Texas."As our customers’ definition of sustainability expands, it’s incumbent on us to be ahead of the curve in understanding their needs," Rees added. "Independent surveys such as this provide clear and impartial feedback, identifying trends and gaps that we can action, to continue to provide solutions that help ensure our customers’ sustainability goals are met or exceeded.""It’s important that we share these results with the wider community as we are all on the journey to be more sustainable," said Victoria Wadsworth, associate vice president of Reputation Marketing at Agilent. "By sharing these learnings, we can spark richer conversations and share best practices that bring everyone closer to their goals. It’s the right thing to do for business and our planet."Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005204/en/ContactsNaomi GoumilloutAgilent Technologies, Inc.+1.781.266.2819naomi.goumillout@agilent.com | Business Wire | 2023-06-08T12:00:00 | Agilent Independent Global Lab Sustainability Survey Sheds Light on Progress Towards Greener Labs | https://finance.yahoo.com/news/agilent-independent-global-lab-sustainability-120000349.html | 64e43790-efd7-3076-ac75-c4e436dfd55a | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "Labs seek guidance in reducing their environmental footprint by increasing efficiency but overall convey optimism on sustainability effortsSANTA CLARA, Calif., June 08, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the results of an independent third-party global survey that will help the industry better understand analytical laboratories’ perceptions, aspirations, and challenges concerning implementing sustainability measures.Conducted on behalf of Agilent by the international market research firm Frost & Sullivan, the survey sought to understand how lab managers globally are thinking about sustainability and reducing the environmental impact of their labs and how vendors like Agilent can help by improving products and services to address their needs and current gaps.The survey took a two-phased approach with 100 qualitative phone interviews, followed by 500 online interviews with experienced lab personnel in Asia, Europe, the United Kingdom, and the United States across all the lab types and market segments Agilent serves. The primary functions of the labs surveyed were analytical services, methods development or validation, process control, monitoring or manufacturing, quality assurance or control, research, and clinical testing.The results indicated that a high percentage (82%) of labs surveyed have already adopted sustainability measures. The top three actions that labs are currently undertaking to reduce their environmental footprint are: reducing carbon and other greenhouse gas emissions (72%), reducing or optimizing water and energy consumption (68%), and improving waste management techniques (60%). Also, 85% of those surveyed expect their vendors to support them in reaching their sustainability goals, now and in the future, and 74% of labs stated that it would be an exclusion criterion for them to engage with a company commercially that did not have a commitment to net zero."A majority of labs stated that information shared by vendors, related to their own goals and objectives towards sustainability, in addition to instrument and product-related information, was important," said Neil Rees, head of Agilent’s ESG Programs. "Our ongoing partnership with My Green Lab and their ACT Environmental Impact Factor Label program ensures that we can offer our customers third-party verified information on the environmental impact of Agilent solutions."Story continues"By providing the necessary verification and transparency of sustainability information, MGL ACT labels help consumers make informed decisions across the lifecycle impact of laboratory products," said James Connelly, My Green Lab CEO. "Participating in ACT is a key way manufacturers demonstrate their commitment to our mission to build a global culture of sustainability in science."Additionally, 54% of labs would be interested in consulting services to assess and improve lab efficiency, followed by instruments and systems that support tracking and monitoring key metrics related to sustainability (44%). Labs are also looking to vendors to provide instrument end-of-life solutions, for example, recycling services (77%) and instrument refurbishment initiatives (51%), such as Agilent’s Certified Pre-Owned Instruments Program. Agilent also showcased a selection of its MGL ACT-labelled products at the ASMS Conference held June 4 - 8 in Houston, Texas."As our customers’ definition of sustainability expands, it’s incumbent on us to be ahead of the curve in understanding their needs," Rees added. "Independent surveys such as this provide clear and impartial feedback, identifying trends and gaps that we can action, to continue to provide solutions that help ensure our customers’ sustainability goals are met or exceeded.""It’s important that we share these results with the wider community as we are all on the journey to be more sustainable," said Victoria Wadsworth, associate vice president of Reputation Marketing at Agilent. "By sharing these learnings, we can spark richer conversations and share best practices that bring everyone closer to their goals. It’s the right thing to do for business and our planet."Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005204/en/ContactsNaomi GoumilloutAgilent Technologies, Inc.+1.781.266.2819naomi.goumillout@agilent.com"
Output: | 1,020 | true | 115.580002 | 115.790001 | 118.540001 | 119.5 | 119.400002 | 121.230003 | UP | UP | UP | UP | UP | 1 | 1 | 1 | 1 | 1 | TRUE | 14 |
A | SANTA CLARA, Calif., May 19, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A), announced today the company intends to appeal the U.S. Patent and Trademarks Office (USPTO) Patent Trial and Appeal Board’s (PTAB) Final Written Decision in connection with the Inter Partes review (IPR) of U.S. Patent Nos. 10,337,001 & 10,900,034 (the Agilent Patents). The PTAB recently reversed the USPTO’s original decision granting claims directed towards chemically modified synthetic CRISPR guide RNA.Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination. The work presented in the two Agilent Patents is also discussed in a publication as part of a broader collaboration with Stanford University in the widely cited paper: Hendel, Ayal et al. "Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells." Nature biotechnology vol. 33,9 (2015): 985-989. doi:10.1038/nbt.3290.The Agilent Patents describe synthesis and testing of hundreds of chemically modified CRISPR guide RNA molecules that were shown to improve the efficiency of CRISPR-based gene editing. Prior to the work done by Agilent’s inventors, it was not known whether the many chemical modifications Agilent made to the various and long guide RNAs would disrupt functionality of the gRNA:Cas enzyme complex. That answer was discovered and disclosed by the Agilent inventors as a multidisciplinary team and using Agilent’s own patented chemical synthesis methods.Building upon its years of expertise in nucleic acid synthesis, Agilent offers the scientific community both research-grade and cGMP-grade guide RNA products incorporating chemical modifications. Agilent’s SureGuide research-grade gRNA products are made and sold in Agilent’s production facility in Santa Clara, California. Agilent’s Nucleic Acid Solutions Division makes and sells its large-scale, cGMP-grade ClinGuide products in its state-of-the art production facilities headquartered in Boulder, Colorado.Story continuesAgilent is confident in the innovative contributions made by its scientists and intends to appeal to the United States Court of Appeals for the Federal Circuit. This patent family also remains open with ongoing prosecution of new claims. Agilent’s Patents will persist until all appeals have been exhausted, and the PTAB decision does not affect Agilent’s continued leadership in CRISPR technologies as a provider of superior-quality guide RNAs. The PTAB’s decision in no way affects Agilent’s ability to make or sell chemically modified gRNA guides.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005808/en/ContactsINVESTOR CONTACT:Parmeet Ahuja+1 408 345 8948Parmeet_Ahuja@agilent.comMEDIA CONTACT:Sarah LittonAgilent Technologies+1 669 255 7696sarah.litton@agilent.com | Business Wire | 2023-05-19T01:25:00 | Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents | https://finance.yahoo.com/news/agilent-appeal-patent-office-decision-012500775.html | 5477d2fd-f0e0-3721-aeb5-9e4184af5fc1 | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "SANTA CLARA, Calif., May 19, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A), announced today the company intends to appeal the U.S. Patent and Trademarks Office (USPTO) Patent Trial and Appeal Board’s (PTAB) Final Written Decision in connection with the Inter Partes review (IPR) of U.S. Patent Nos. 10,337,001 & 10,900,034 (the Agilent Patents). The PTAB recently reversed the USPTO’s original decision granting claims directed towards chemically modified synthetic CRISPR guide RNA.Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination. The work presented in the two Agilent Patents is also discussed in a publication as part of a broader collaboration with Stanford University in the widely cited paper: Hendel, Ayal et al. "Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells." Nature biotechnology vol. 33,9 (2015): 985-989. doi:10.1038/nbt.3290.The Agilent Patents describe synthesis and testing of hundreds of chemically modified CRISPR guide RNA molecules that were shown to improve the efficiency of CRISPR-based gene editing. Prior to the work done by Agilent’s inventors, it was not known whether the many chemical modifications Agilent made to the various and long guide RNAs would disrupt functionality of the gRNA:Cas enzyme complex. That answer was discovered and disclosed by the Agilent inventors as a multidisciplinary team and using Agilent’s own patented chemical synthesis methods.Building upon its years of expertise in nucleic acid synthesis, Agilent offers the scientific community both research-grade and cGMP-grade guide RNA products incorporating chemical modifications. Agilent’s SureGuide research-grade gRNA products are made and sold in Agilent’s production facility in Santa Clara, California. Agilent’s Nucleic Acid Solutions Division makes and sells its large-scale, cGMP-grade ClinGuide products in its state-of-the art production facilities headquartered in Boulder, Colorado.Story continuesAgilent is confident in the innovative contributions made by its scientists and intends to appeal to the United States Court of Appeals for the Federal Circuit. This patent family also remains open with ongoing prosecution of new claims. Agilent’s Patents will persist until all appeals have been exhausted, and the PTAB decision does not affect Agilent’s continued leadership in CRISPR technologies as a provider of superior-quality guide RNAs. The PTAB’s decision in no way affects Agilent’s ability to make or sell chemically modified gRNA guides.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005808/en/ContactsINVESTOR CONTACT:Parmeet Ahuja+1 408 345 8948Parmeet_Ahuja@agilent.comMEDIA CONTACT:Sarah LittonAgilent Technologies+1 669 255 7696sarah.litton@agilent.com"
Output: | 889 | true | 128.660004 | 129.089996 | 128.639999 | 120.989998 | 119.489998 | 120.419998 | UP | DOWN | DOWN | DOWN | DOWN | 1 | 0 | 0 | 0 | 0 | TRUE | 15 |
A | Agilent Technologies A reported second-quarter fiscal 2023 earnings of $1.27 per share, which came in line with the Zacks Consensus Estimate. The bottom line increased by 12.4% from the year-ago fiscal quarter’s level.Revenues of $1.72 billion surpassed the Zacks Consensus Estimate of $1.67 billion. The top line was up 6.8% on a reported basis and 9.5% on a core basis from the respective year-ago fiscal quarter’s levels.Top-line growth was driven by strong momentum across Food, Academia & Gov’t and Chemistry & Advanced Materials markets. A strong performance in China also contributed well.Segmental Top Line DetailsAgilent has three reporting segments, namely, Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG) and Diagnostics and Genomics Group (DGG).LSAG: The segment accounted for $968 million or 56% of its total revenues, up 8% on a reported basis and 10% on a core basis from the respective prior-year fiscal quarter’s levels. This was driven by strong performance in the Chemical & Advanced Materials, Food and Academic & Gov’t markets. Strength in LC and LCMS and lab consumables also aided results.ACG: Revenues from the segment were $387 million, accounting for 23% of total revenues. Also, the top line improved by 10% from the prior-year fiscal quarter’s reading on a reported basis and 13% on a core basis, driven by strength in services attached to new instrument installations as well as expanding service offerings for the existing instrument base.DGG: Revenues increased 1% from the prior-year fiscal quarter’s figure on a reported basis and 3% on a core basis to $362 million, accounting for the remaining 21% of total revenues. Segmental growth was attributed to strength in the NASD and pathology businesses. Also, solid momentum in companion diagnostics pharma services contributed well.Agilent Technologies, Inc. Price, Consensus and EPS SurpriseAgilent Technologies, Inc. Price, Consensus and EPS SurpriseAgilent Technologies, Inc. price-consensus-eps-surprise-chart | Agilent Technologies, Inc. QuoteStory continuesOperating ResultsFor the fiscal second quarter, gross margin in the LSAG segment expanded by 90 basis points (bps) to 59.9% from the prior-year fiscal quarter’s number. ACG’s gross margin contracted 10 bps to 47%. DGG’s gross margin contracted 420 bps from the year-ago fiscal quarter’s actuals to 51.8%.Research & development (R&D) costs were $126 million, up 9.6% from the prior-year fiscal quarter’s number. Selling, general & administrative (SG&A) expenses were $415 million, up 7.5% from the year-earlier fiscal quarter’s figure. As a percentage of revenues, R&D expenses expanded 10 bps year over year to 7.3%. Meanwhile, SG&A expenses expanded 20 bps year over year to 24.2%.Operating margin for the fiscal first quarter was 22.3%, which contracted 10 bps from the year-earlier fiscal quarter’s figure.Segment-wise, the operating margin for LSAG was up 180 bps from the year-earlier fiscal quarter’s level of 27.3%. ACG’s operating margin was 26.6%, up 200 bps from the year-ago fiscal quarter’s level. DGG segment’s operating margin contracted 530 bps to 20.2% from the year-ago fiscal quarter’s figure.Balance Sheet & Cash FlowAs of Apr 30, 2023, Agilent’s cash and cash equivalents were $1.18 billion, down from $1.25 billion on Jan 31, 2023.Accounts receivables were $1.4 billion at the end of second-quarter fiscal 2023, down from $1.5 billion at the end of first-quarter fiscal 2023.Long-term debt was $2.733 billion for the reported quarter, which remained flat as compared with the prior fiscal quarter.Agilent generated $398 million in cash from operations during the reported quarter, up from $296 million generated in the previous quarter.Further, it returned $151 million to shareholders, out of which dividend payments accounted for $66 million and share repurchases accounted for the remaining $85 million.GuidanceFor the fiscal third quarter of 2023, management expects revenues of $1.640-$1.675 billion, suggesting growth between 4.5% and 2.5% on a core basis from the year-ago fiscal quarter’s actuals. The Zacks Consensus Estimate for the same is pegged at $1.76 billion.Non-GAAP earnings per share are expected to be $1.36-$1.38. The consensus mark for fiscal third-quarter earnings stands at $1.43 per share.For fiscal 2023, management lowered its revenue guidance from the band of $7.03-$7.1 billion to $6.93-7.03 billion, implying a growth of 1.2-2.7% on a reported basis and 3-4.5% on a core basis from the respective fiscal 2022 figures. The Zacks Consensus Estimate for the same is pegged at $7.07 billion.Management also updated the guidance for fiscal 2023 non-GAAP earnings per share downward from $5.65-$5.70 to $5.60-$5.65. The consensus mark for fiscal 2023 earnings is pegged at $5.68 per share.Zacks Rank & Other Stocks to ConsiderCurrently, Agilent carries a Zacks Rank #3 (Hold).Investors interested in the broader technology sector can consider some better-ranked stocks like Ciena CIEN, CrowdStrike CRWD and AMETEK AME. Ciena, CrowdStrike and AMETEK each carry a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Ciena shares have lost 14.9% in the year-to-date time frame. The Zacks Consensus Estimate for CIEN’s fiscal year 2023 earnings is pegged at $2.81 per share, suggesting an increase of 47.9% from the prior year’s reported figure.CrowdStrike shares have risen 27% in the year-to-date period. The Zacks Consensus Estimate for CRWD’s 2023 earnings is pegged at $2.30 per share, suggesting growth of 49.4% from the prior year’s reported figure.AMETEK shares have rallied 3.4% year to date. The Zacks Consensus Estimate for AME’s 2023 earnings is pegged at $6.11 per share, suggesting an increase of 7.57% from the prior year’s reported figure.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCiena Corporation (CIEN) : Free Stock Analysis ReportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportAMETEK, Inc. (AME) : Free Stock Analysis ReportCrowdStrike (CRWD) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | 2023-05-24T17:17:00 | Agilent (A) Q2 Earnings Match Estimates, Revenues Rise Y/Y | https://finance.yahoo.com/news/agilent-q2-earnings-match-estimates-171700417.html | e9307f15-4308-33d8-a649-57f4df3530b1 | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "Agilent Technologies A reported second-quarter fiscal 2023 earnings of $1.27 per share, which came in line with the Zacks Consensus Estimate. The bottom line increased by 12.4% from the year-ago fiscal quarter’s level.Revenues of $1.72 billion surpassed the Zacks Consensus Estimate of $1.67 billion. The top line was up 6.8% on a reported basis and 9.5% on a core basis from the respective year-ago fiscal quarter’s levels.Top-line growth was driven by strong momentum across Food, Academia & Gov’t and Chemistry & Advanced Materials markets. A strong performance in China also contributed well.Segmental Top Line DetailsAgilent has three reporting segments, namely, Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG) and Diagnostics and Genomics Group (DGG).LSAG: The segment accounted for $968 million or 56% of its total revenues, up 8% on a reported basis and 10% on a core basis from the respective prior-year fiscal quarter’s levels. This was driven by strong performance in the Chemical & Advanced Materials, Food and Academic & Gov’t markets. Strength in LC and LCMS and lab consumables also aided results.ACG: Revenues from the segment were $387 million, accounting for 23% of total revenues. Also, the top line improved by 10% from the prior-year fiscal quarter’s reading on a reported basis and 13% on a core basis, driven by strength in services attached to new instrument installations as well as expanding service offerings for the existing instrument base.DGG: Revenues increased 1% from the prior-year fiscal quarter’s figure on a reported basis and 3% on a core basis to $362 million, accounting for the remaining 21% of total revenues. Segmental growth was attributed to strength in the NASD and pathology businesses. Also, solid momentum in companion diagnostics pharma services contributed well.Agilent Technologies, Inc. Price, Consensus and EPS SurpriseAgilent Technologies, Inc. Price, Consensus and EPS SurpriseAgilent Technologies, Inc. price-consensus-eps-surprise-chart | Agilent Technologies, Inc. QuoteStory continuesOperating ResultsFor the fiscal second quarter, gross margin in the LSAG segment expanded by 90 basis points (bps) to 59.9% from the prior-year fiscal quarter’s number. ACG’s gross margin contracted 10 bps to 47%. DGG’s gross margin contracted 420 bps from the year-ago fiscal quarter’s actuals to 51.8%.Research & development (R&D) costs were $126 million, up 9.6% from the prior-year fiscal quarter’s number. Selling, general & administrative (SG&A) expenses were $415 million, up 7.5% from the year-earlier fiscal quarter’s figure. As a percentage of revenues, R&D expenses expanded 10 bps year over year to 7.3%. Meanwhile, SG&A expenses expanded 20 bps year over year to 24.2%.Operating margin for the fiscal first quarter was 22.3%, which contracted 10 bps from the year-earlier fiscal quarter’s figure.Segment-wise, the operating margin for LSAG was up 180 bps from the year-earlier fiscal quarter’s level of 27.3%. ACG’s operating margin was 26.6%, up 200 bps from the year-ago fiscal quarter’s level. DGG segment’s operating margin contracted 530 bps to 20.2% from the year-ago fiscal quarter’s figure.Balance Sheet & Cash FlowAs of Apr 30, 2023, Agilent’s cash and cash equivalents were $1.18 billion, down from $1.25 billion on Jan 31, 2023.Accounts receivables were $1.4 billion at the end of second-quarter fiscal 2023, down from $1.5 billion at the end of first-quarter fiscal 2023.Long-term debt was $2.733 billion for the reported quarter, which remained flat as compared with the prior fiscal quarter.Agilent generated $398 million in cash from operations during the reported quarter, up from $296 million generated in the previous quarter.Further, it returned $151 million to shareholders, out of which dividend payments accounted for $66 million and share repurchases accounted for the remaining $85 million.GuidanceFor the fiscal third quarter of 2023, management expects revenues of $1.640-$1.675 billion, suggesting growth between 4.5% and 2.5% on a core basis from the year-ago fiscal quarter’s actuals. The Zacks Consensus Estimate for the same is pegged at $1.76 billion.Non-GAAP earnings per share are expected to be $1.36-$1.38. The consensus mark for fiscal third-quarter earnings stands at $1.43 per share.For fiscal 2023, management lowered its revenue guidance from the band of $7.03-$7.1 billion to $6.93-7.03 billion, implying a growth of 1.2-2.7% on a reported basis and 3-4.5% on a core basis from the respective fiscal 2022 figures. The Zacks Consensus Estimate for the same is pegged at $7.07 billion.Management also updated the guidance for fiscal 2023 non-GAAP earnings per share downward from $5.65-$5.70 to $5.60-$5.65. The consensus mark for fiscal 2023 earnings is pegged at $5.68 per share.Zacks Rank & Other Stocks to ConsiderCurrently, Agilent carries a Zacks Rank #3 (Hold).Investors interested in the broader technology sector can consider some better-ranked stocks like Ciena CIEN, CrowdStrike CRWD and AMETEK AME. Ciena, CrowdStrike and AMETEK each carry a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Ciena shares have lost 14.9% in the year-to-date time frame. The Zacks Consensus Estimate for CIEN’s fiscal year 2023 earnings is pegged at $2.81 per share, suggesting an increase of 47.9% from the prior year’s reported figure.CrowdStrike shares have risen 27% in the year-to-date period. The Zacks Consensus Estimate for CRWD’s 2023 earnings is pegged at $2.30 per share, suggesting growth of 49.4% from the prior year’s reported figure.AMETEK shares have rallied 3.4% year to date. The Zacks Consensus Estimate for AME’s 2023 earnings is pegged at $6.11 per share, suggesting an increase of 7.57% from the prior year’s reported figure.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCiena Corporation (CIEN) : Free Stock Analysis ReportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportAMETEK, Inc. (AME) : Free Stock Analysis ReportCrowdStrike (CRWD) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research"
Output: | 1,658 | true | 121.410004 | 119.489998 | 120.419998 | 117.730003 | 115.669998 | 116.260002 | DOWN | DOWN | DOWN | DOWN | DOWN | 0 | 0 | 0 | 0 | 0 | FALSE | 16 |
A | *White House, Republicans resume US debt ceiling talks*Stocks hold declines after release of Fed minutes*Citigroup drops after scrapping Mexico unit sale*Indexes down: Dow 0.77%, S&P 0.73%, Nasdaq 0.61%(Adds official closing market details throughout)By Lewis Krauskopf, Shreyashi Sanyal and Shristi Achar AMay 24 (Reuters) - Wall Street's main indexes ended lower on Wednesday as talks between the White House and Republican representatives on raising the U.S. debt ceiling dragged on without a deal.The lack of progress on raising the U.S. government's $31.4 trillion debt limit ahead of a June 1 deadline, with several rounds of inconclusive talks, has made investors edgier as the risk of a catastrophic default looms larger.Democratic President Joe Biden and top congressional Republican Kevin McCarthy's negotiators held what the White House called productive talks."Up until yesterday, investors have been very optimistic around the U.S. debt ceiling resolution," said Angelo Kourkafas, senior investment strategist at Edward Jones. "But now as we get closer ... to the June 1st X-date, we are seeing some caution again.”The Dow Jones Industrial Average fell 255.59 points, or 0.77%, to 32,799.92, the S&P 500 lost 30.34 points, or 0.73%, to 4,115.24 and the Nasdaq Composite dropped 76.08 points, or 0.61%, to 12,484.16.Ten of the 11 S&P 500 sectors ended in negative territory, with real estate falling the most. Energy was the lone sector gainer.The CBOE Volatility Index, known as Wall Street's fear gauge, hovered around three-week highs.Federal Reserve policy was also in focus. Stocks held their declines after the release of minutes from the Fed's May 2-3 meeting, showing that Fed officials "generally agreed" last month that the need for further interest rate increases "had become less certain."Investors expect the central bank to pause its aggressive rate hiking campaign at its June 13-14 meeting.Story continuesFed Governor Christopher Waller said he is concerned about the lack of progress on inflation, and while skipping an interest rate hike at the central bank's meeting next month may be possible, an end to the hiking campaign is not likely.“The economy is still doing OK, and there really is not, from the Fed’s perspective, a reason to back away from a tighter monetary policy,” said Paul Nolte, senior wealth advisor and market strategist at Murphy & Sylvest Wealth Management.In company news, Citigroup Inc shares fell 3.1% as the bank scrapped a $7 billion sale of its Mexican consumer unit Banamex and will list it instead.Agilent Technologies Inc shares shed about 6% after the company cut its annual sales and profit forecasts.Shares of TurboTax-owner Intuit Inc dropped 7.5% after a disappointing profit forecast.Declining issues outnumbered advancing ones on the NYSE by a 3.71-to-1 ratio; on Nasdaq, a 2.34-to-1 ratio favored decliners.The S&P 500 posted no new 52-week highs and 14 new lows; the Nasdaq Composite recorded 38 new highs and 110 new lows.About 9.7 billion shares changed hands in U.S. exchanges, compared with the 10.5 billion daily average over the last 20 sessions. (Reporting by Lewis Krauskopf and Sinéad Carew in New York, Shreyashi Sanyal and Shristi Achar A in Bengaluru Editing by Vinay Dwivedi and David Gregorio) | Reuters | 2023-05-24T20:16:53 | US STOCKS-Wall St ends down as debt-ceiling clouds hover | https://finance.yahoo.com/news/us-stocks-wall-st-ends-201653651.html | 1eeea160-b463-372c-b344-85ef6fb3a4d8 | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "*White House, Republicans resume US debt ceiling talks*Stocks hold declines after release of Fed minutes*Citigroup drops after scrapping Mexico unit sale*Indexes down: Dow 0.77%, S&P 0.73%, Nasdaq 0.61%(Adds official closing market details throughout)By Lewis Krauskopf, Shreyashi Sanyal and Shristi Achar AMay 24 (Reuters) - Wall Street's main indexes ended lower on Wednesday as talks between the White House and Republican representatives on raising the U.S. debt ceiling dragged on without a deal.The lack of progress on raising the U.S. government's $31.4 trillion debt limit ahead of a June 1 deadline, with several rounds of inconclusive talks, has made investors edgier as the risk of a catastrophic default looms larger.Democratic President Joe Biden and top congressional Republican Kevin McCarthy's negotiators held what the White House called productive talks."Up until yesterday, investors have been very optimistic around the U.S. debt ceiling resolution," said Angelo Kourkafas, senior investment strategist at Edward Jones. "But now as we get closer ... to the June 1st X-date, we are seeing some caution again.”The Dow Jones Industrial Average fell 255.59 points, or 0.77%, to 32,799.92, the S&P 500 lost 30.34 points, or 0.73%, to 4,115.24 and the Nasdaq Composite dropped 76.08 points, or 0.61%, to 12,484.16.Ten of the 11 S&P 500 sectors ended in negative territory, with real estate falling the most. Energy was the lone sector gainer.The CBOE Volatility Index, known as Wall Street's fear gauge, hovered around three-week highs.Federal Reserve policy was also in focus. Stocks held their declines after the release of minutes from the Fed's May 2-3 meeting, showing that Fed officials "generally agreed" last month that the need for further interest rate increases "had become less certain."Investors expect the central bank to pause its aggressive rate hiking campaign at its June 13-14 meeting.Story continuesFed Governor Christopher Waller said he is concerned about the lack of progress on inflation, and while skipping an interest rate hike at the central bank's meeting next month may be possible, an end to the hiking campaign is not likely.“The economy is still doing OK, and there really is not, from the Fed’s perspective, a reason to back away from a tighter monetary policy,” said Paul Nolte, senior wealth advisor and market strategist at Murphy & Sylvest Wealth Management.In company news, Citigroup Inc shares fell 3.1% as the bank scrapped a $7 billion sale of its Mexican consumer unit Banamex and will list it instead.Agilent Technologies Inc shares shed about 6% after the company cut its annual sales and profit forecasts.Shares of TurboTax-owner Intuit Inc dropped 7.5% after a disappointing profit forecast.Declining issues outnumbered advancing ones on the NYSE by a 3.71-to-1 ratio; on Nasdaq, a 2.34-to-1 ratio favored decliners.The S&P 500 posted no new 52-week highs and 14 new lows; the Nasdaq Composite recorded 38 new highs and 110 new lows.About 9.7 billion shares changed hands in U.S. exchanges, compared with the 10.5 billion daily average over the last 20 sessions. (Reporting by Lewis Krauskopf and Sinéad Carew in New York, Shreyashi Sanyal and Shristi Achar A in Bengaluru Editing by Vinay Dwivedi and David Gregorio)"
Output: | 817 | true | 121.410004 | 119.489998 | 120.419998 | 117.730003 | 115.669998 | 116.260002 | DOWN | DOWN | DOWN | DOWN | DOWN | 0 | 0 | 0 | 0 | 0 | TRUE | 17 |
A | Self-aware solutions making mass spectrometry more accessibleSANTA CLARA, Calif., June 02, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced new mass spectrometry solutions on show at the 71st ASMS Conference on Mass Spectrometry and Allied Topics, being held June 4 - 8 in Houston, Texas. Agilent is a global leader in the mass spectrometry market, providing advanced, intelligent instruments featuring improved analytical performance solutions for analytical labs worldwide."Agilent is leading the way in the trend towards developing more self-aware and intelligent instruments," said Sudharshana Seshadri, vice president and general manager of Agilent’s Liquid Chromatography, Mass Spectrometry, and Automation Divisions. "Our goal is to make our customers’ lives easier, so they worry less about their instruments and can focus more on their science."New products will be highlighted at ASMS that add to Agilent’s powerful LC/MS solutions portfolio. A new LC/TQ will be introduced that incorporates numerous intelligence features oriented towards demanding routine analysis applications—also, a next-generation LC/Q-TOF featuring new instrument architecture also coupled with intelligence to maximize productivity.The new Agilent 1260 Infinity II Hybrid Multisampler will be on show, an HPLC autosampler that offers classical Flow-through and Agilent Feed Injection modes. For example, food LC/MS analysis sample preparation often requires a strong solvent, which can be challenging. The solvent effect can lead to sample breakthrough and poor peak shapes, especially when the injection volume increases. Agilent Feed Injection mode is a unique technology that mediates a strong sample solvent effect by infusing the sample continuously into the mobile phase stream, improving peak shapes and sensitivity.New Agilent MassHunter Software Suite highlights include the Agilent AI Peak Integration Software for MassHunter Quant, which replaces manual peak integration with adaptable AI-assisted peak detection and integration. Analytical test labs using GC/MS Single Quadrupole will benefit from deep learning and continuous learning feedback that improves model performance over time, particularly for rare compound detection.Story continuesAlso, Agilent’s MassHunter BioConfirm 12.1 Software enables the interpretation of ECD fragmentation and enhancements to strengthen the peptide mapping workflow. BioConfirm 12.1 continues to offer powerful biopharma workflows for our customers with the highest quality oligonucleotide data, extracting information to assess impurities, confirm intact protein molecular weights, peptide sequence coverage, and the location of post-translational modifications, and the identification of released glycans."These new products demonstrate how intelligence features continue to improve analytical performance and lab productivity, automating difficult and challenging tasks, making mass spectrometry more accessible to all researchers," said Ken Suzuki, vice president and general manager of Agilent’s Mass Spectrometry Division.Agilent will hold several events at ASMS 2023. Agilent will host its annual Ion Mobility User Meeting on Sunday, June 4, from 2:00 – 5:00 p.m. at the Marriott Marquis Hotel in Houston. Agilent will also host breakfast sessions Monday, June 5 – Wednesday, June 7, from 7:00 – 8:15 a.m. in the George R. Brown Convention Center and the Agilent Hospitality Suite. Additional information on these and other events is available at Agilent at ASMS.ASMS attendees are invited to visit Agilent's Exhibition Booth #600 at the George R. Brown Convention Center and to spend time at the Agilent Hospitality Suite at the Hilton Americas Houston, Ballroom EF, Monday, June 5 – Wednesday, June 7 from 8:00 – 10:30 p.m. Agilent is a corporate member of ASMS and multi-year co-sponsor of the annual event.Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230602005072/en/ContactsMEDIA CONTACT Naomi GoumilloutAgilent Technologies Inc.+1.781.266.2819naomi.goumillout@agilent.com | Business Wire | 2023-06-02T12:00:00 | Agilent Intelligent Mass Spectrometry Solutions to Inspire at ASMS 2023 | https://finance.yahoo.com/news/agilent-intelligent-mass-spectrometry-solutions-120000872.html | f22de1f1-e6b3-3a5f-8e31-3c430007cbad | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "Self-aware solutions making mass spectrometry more accessibleSANTA CLARA, Calif., June 02, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced new mass spectrometry solutions on show at the 71st ASMS Conference on Mass Spectrometry and Allied Topics, being held June 4 - 8 in Houston, Texas. Agilent is a global leader in the mass spectrometry market, providing advanced, intelligent instruments featuring improved analytical performance solutions for analytical labs worldwide."Agilent is leading the way in the trend towards developing more self-aware and intelligent instruments," said Sudharshana Seshadri, vice president and general manager of Agilent’s Liquid Chromatography, Mass Spectrometry, and Automation Divisions. "Our goal is to make our customers’ lives easier, so they worry less about their instruments and can focus more on their science."New products will be highlighted at ASMS that add to Agilent’s powerful LC/MS solutions portfolio. A new LC/TQ will be introduced that incorporates numerous intelligence features oriented towards demanding routine analysis applications—also, a next-generation LC/Q-TOF featuring new instrument architecture also coupled with intelligence to maximize productivity.The new Agilent 1260 Infinity II Hybrid Multisampler will be on show, an HPLC autosampler that offers classical Flow-through and Agilent Feed Injection modes. For example, food LC/MS analysis sample preparation often requires a strong solvent, which can be challenging. The solvent effect can lead to sample breakthrough and poor peak shapes, especially when the injection volume increases. Agilent Feed Injection mode is a unique technology that mediates a strong sample solvent effect by infusing the sample continuously into the mobile phase stream, improving peak shapes and sensitivity.New Agilent MassHunter Software Suite highlights include the Agilent AI Peak Integration Software for MassHunter Quant, which replaces manual peak integration with adaptable AI-assisted peak detection and integration. Analytical test labs using GC/MS Single Quadrupole will benefit from deep learning and continuous learning feedback that improves model performance over time, particularly for rare compound detection.Story continuesAlso, Agilent’s MassHunter BioConfirm 12.1 Software enables the interpretation of ECD fragmentation and enhancements to strengthen the peptide mapping workflow. BioConfirm 12.1 continues to offer powerful biopharma workflows for our customers with the highest quality oligonucleotide data, extracting information to assess impurities, confirm intact protein molecular weights, peptide sequence coverage, and the location of post-translational modifications, and the identification of released glycans."These new products demonstrate how intelligence features continue to improve analytical performance and lab productivity, automating difficult and challenging tasks, making mass spectrometry more accessible to all researchers," said Ken Suzuki, vice president and general manager of Agilent’s Mass Spectrometry Division.Agilent will hold several events at ASMS 2023. Agilent will host its annual Ion Mobility User Meeting on Sunday, June 4, from 2:00 – 5:00 p.m. at the Marriott Marquis Hotel in Houston. Agilent will also host breakfast sessions Monday, June 5 – Wednesday, June 7, from 7:00 – 8:15 a.m. in the George R. Brown Convention Center and the Agilent Hospitality Suite. Additional information on these and other events is available at Agilent at ASMS.ASMS attendees are invited to visit Agilent's Exhibition Booth #600 at the George R. Brown Convention Center and to spend time at the Agilent Hospitality Suite at the Hilton Americas Houston, Ballroom EF, Monday, June 5 – Wednesday, June 7 from 8:00 – 10:30 p.m. Agilent is a corporate member of ASMS and multi-year co-sponsor of the annual event.Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230602005072/en/ContactsMEDIA CONTACT Naomi GoumilloutAgilent Technologies Inc.+1.781.266.2819naomi.goumillout@agilent.com"
Output: | 1,061 | true | 118.580002 | 118.349998 | 117.440002 | 116.589996 | 114.690002 | 115.790001 | DOWN | DOWN | DOWN | DOWN | DOWN | 0 | 0 | 0 | 0 | 0 | TRUE | 18 |
A | Agilent Technologies A is set to report its second-quarter fiscal 2023 results on May 23.For the fiscal second quarter, A expects revenues of $1.655-$1.680 billion, suggesting growth between 6% and 7.5% on a core basis from the year-ago fiscal quarter’s actuals. The Zacks Consensus Estimate for the same is pegged at $1.67 billion, implying growth of 3.8% from the year-ago fiscal quarter’s reported figure.Agilent’s non-GAAP earnings are expected to be $1.24-1.27 per share. The Zacks Consensus Estimate for earnings is pegged at $1.27 per share, indicating growth of 12.4% from the year-ago fiscal quarter’s reported figure.Agilent’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average being 7.03%.Agilent Technologies, Inc. Price and EPS SurpriseAgilent Technologies, Inc. Price and EPS SurpriseAgilent Technologies, Inc. price-eps-surprise | Agilent Technologies, Inc. QuoteKey Factors to NoteAgilent’s performance in the fiscal second quarter is likely to have benefited from solid momentum in the chemical & advanced materials markets.Additionally, A’s strength in the Life Sciences & Applied Markets Group (LSAG) segment, owing to growth in Spectra business and strengthening spectroscopy base across various end markets, is expected to have contributed to its performance in the quarter under review.The Zacks Consensus Estimate for LSAG is pegged at $938 million, implying growth of 4.7% from the year-ago fiscal quarter’s reported figure.Moreover, during the fiscal second quarter, Agilent’s Cross Lab Group (ACG) segment is likely to have benefited from service business growth on the back of strong customer-lab operations.The Zacks Consensus Estimate for ACG is pegged at $367 million, implying growth of 3.96% from the year-ago fiscal quarter’s reported figure.Agilent’s Strength in NASD and Genomics portfolio is likely to have contributed to the Diagnostics and Genomics Group (DGG) segment in the second quarter.The Zacks Consensus Estimate for DGG is pegged at $362 million, implying growth of 1.1% from the year-ago fiscal quarter’s reported figure.Further, strength in the Americas region and growth in the European businesses are expected to have remained tailwinds in the quarter under discussion.However, mounting expenses and macroeconomic headwinds are likely to have remained a headwind in the quarter under review.Story continuesWhat Our Model SaysOur proven model predicts an earnings beat for Agilent. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP FilterAgilent has an Earnings ESP of +0.40% and a Zacks Rank #3 at present.Other Stocks to ConsiderHere are some stocks worth considering as our model shows that these have the right combination of elements to beat on earnings this season.Autodesk ADSK has an Earnings ESP of +1.76% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.ADSK is scheduled to release first-quarter 2024 results on May 25. The Zacks Consensus Estimate for ADSK’s earnings is pegged at $1.55 per share, suggesting a rise of 8.4% year over year.NVIDIA NVDA has an Earnings ESP of +2.43% and carries a Zacks Rank #3 at present.NVDA is slated to report first-quarter fiscal 2024 results on May 24. The Zacks Consensus Estimate for NVDA’s first-quarter earnings is pegged at 92 cents per share, indicating a year-over-year decline of 32.4%.Costco Wholesale COST has an Earnings ESP of +0.04% and a Zacks Rank #3 at present.COST is scheduled to report third-quarter fiscal 2023 results on May 25. The Zacks Consensus Estimate for COST’s earnings is pegged at $3.32 per share, suggesting an increase of 4.7% from the prior-year quarter’s reported figure.Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportNVIDIA Corporation (NVDA) : Free Stock Analysis ReportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportCostco Wholesale Corporation (COST) : Free Stock Analysis ReportAutodesk, Inc. (ADSK) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | 2023-05-19T15:08:03 | Agilent Technologies (A) to Post Q2 Earnings: What's in Store? | https://finance.yahoo.com/news/agilent-technologies-post-q2-earnings-150803307.html | 619f9fb9-c102-37fc-8b8c-50c11237b9a7 | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "Agilent Technologies A is set to report its second-quarter fiscal 2023 results on May 23.For the fiscal second quarter, A expects revenues of $1.655-$1.680 billion, suggesting growth between 6% and 7.5% on a core basis from the year-ago fiscal quarter’s actuals. The Zacks Consensus Estimate for the same is pegged at $1.67 billion, implying growth of 3.8% from the year-ago fiscal quarter’s reported figure.Agilent’s non-GAAP earnings are expected to be $1.24-1.27 per share. The Zacks Consensus Estimate for earnings is pegged at $1.27 per share, indicating growth of 12.4% from the year-ago fiscal quarter’s reported figure.Agilent’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average being 7.03%.Agilent Technologies, Inc. Price and EPS SurpriseAgilent Technologies, Inc. Price and EPS SurpriseAgilent Technologies, Inc. price-eps-surprise | Agilent Technologies, Inc. QuoteKey Factors to NoteAgilent’s performance in the fiscal second quarter is likely to have benefited from solid momentum in the chemical & advanced materials markets.Additionally, A’s strength in the Life Sciences & Applied Markets Group (LSAG) segment, owing to growth in Spectra business and strengthening spectroscopy base across various end markets, is expected to have contributed to its performance in the quarter under review.The Zacks Consensus Estimate for LSAG is pegged at $938 million, implying growth of 4.7% from the year-ago fiscal quarter’s reported figure.Moreover, during the fiscal second quarter, Agilent’s Cross Lab Group (ACG) segment is likely to have benefited from service business growth on the back of strong customer-lab operations.The Zacks Consensus Estimate for ACG is pegged at $367 million, implying growth of 3.96% from the year-ago fiscal quarter’s reported figure.Agilent’s Strength in NASD and Genomics portfolio is likely to have contributed to the Diagnostics and Genomics Group (DGG) segment in the second quarter.The Zacks Consensus Estimate for DGG is pegged at $362 million, implying growth of 1.1% from the year-ago fiscal quarter’s reported figure.Further, strength in the Americas region and growth in the European businesses are expected to have remained tailwinds in the quarter under discussion.However, mounting expenses and macroeconomic headwinds are likely to have remained a headwind in the quarter under review.Story continuesWhat Our Model SaysOur proven model predicts an earnings beat for Agilent. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP FilterAgilent has an Earnings ESP of +0.40% and a Zacks Rank #3 at present.Other Stocks to ConsiderHere are some stocks worth considering as our model shows that these have the right combination of elements to beat on earnings this season.Autodesk ADSK has an Earnings ESP of +1.76% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.ADSK is scheduled to release first-quarter 2024 results on May 25. The Zacks Consensus Estimate for ADSK’s earnings is pegged at $1.55 per share, suggesting a rise of 8.4% year over year.NVIDIA NVDA has an Earnings ESP of +2.43% and carries a Zacks Rank #3 at present.NVDA is slated to report first-quarter fiscal 2024 results on May 24. The Zacks Consensus Estimate for NVDA’s first-quarter earnings is pegged at 92 cents per share, indicating a year-over-year decline of 32.4%.Costco Wholesale COST has an Earnings ESP of +0.04% and a Zacks Rank #3 at present.COST is scheduled to report third-quarter fiscal 2023 results on May 25. The Zacks Consensus Estimate for COST’s earnings is pegged at $3.32 per share, suggesting an increase of 4.7% from the prior-year quarter’s reported figure.Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportNVIDIA Corporation (NVDA) : Free Stock Analysis ReportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportCostco Wholesale Corporation (COST) : Free Stock Analysis ReportAutodesk, Inc. (ADSK) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research"
Output: | 1,129 | true | 128.660004 | 129.089996 | 128.639999 | 120.989998 | 119.489998 | 120.419998 | UP | DOWN | DOWN | DOWN | DOWN | 1 | 0 | 0 | 0 | 0 | TRUE | 19 |
A | SANTA CLARA, Calif., June 05, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced two new liquid chromatography mass spectrometry systems (LCMS), the Agilent 6495D LC/TQ and the Agilent Revident LC/Q-TOF. Facilitating the high-end performance of the Revident LC/Q-TOF, Agilent is also announcing the new Agilent MassHunter Explorer Profiling software and the new Agilent ChemVista library manager software.The superior Agilent 6495 Triple Quadrupole LC/MS (LC/TQ) System is ideal for demanding and challenging targeted analysis applications requiring the highest analytical sensitivity. The 6495 LC/TQ incorporates numerous intelligence features that address the critical transition between the ‘discovery phase’ of research and the ‘translational phase’ where studying a large volume of samples is crucial for generating meaningful scientific insights. The 6495 LC/TQ instrument was built for research with production-ready robustness, ensuring increased sample measurements due to greater efficiency and reduced instrument downtime. Intelligence features also include sub-millisecond dwell times and Intelligent Reflex that provides fast, sensitive, high-quality data, while early maintenance feedback and scheduled tuning keep the LC/TQ in peak working condition.The Agilent Revident Quadrupole Time-of-Flight LC/MS (LC/QTOF) System offers an entirely new instrument architecture coupled with instrument intelligence for maximized operation time and productivity. Revident is targeted toward food safety and environmental analysis but also has applications in other small molecule markets, from metabolomics to pharmaceuticals. Incorporating the new MassHunter Explorer Software, untargeted analyses are simplified by allowing data exploration, including statistical analysis and identification in a single software. Tasks can be performed faster with fewer errors and less expertise without compromising quality or accuracy. Additionally, the new ChemVista library manager software integrates extensive curated libraries. It enables third-party import and export into a tool that conveniently connects to MassHunter, allowing access to vast external databases for identification workflows.Story continues"The new 6495D LC/TQ offers significant improvements in sensitivity and speed over the current 6495C, which is already a reputable high-end LC/TQ, while the Revident LC/Q-TOF is the first of a new generation of LC/Q-TOF systems," said Sudharshana Seshadri, vice president and general manager of Agilent’s Liquid Chromatography, Mass Spectrometry, and Automation Divisions."This launch expands the instrument intelligence from our TQ product line to our Q-TOF. Revident also includes a novel detection system that greatly enhances spectral purity, and combined with our new MassHunter Explorer Profiling and ChemVista library manager software, the Revident LC/Q-TOF is revolutionizing our customers’ experience with LC/Q-TOF—providing the highest, yet relevant, performance for meaningful scientific insights," Seshadri added.Agilent is a leading solution provider of proven, robust, and reliable mass spectrometry technologies to a range of segments and a wide array of applications in the bio/pharma, life science research, food, and environmental markets. These new technological capabilities enable Agilent’s customers to increase data quality and interpretation while reducing the time and human attention required—more easily adapting to ever-changing market needs.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230605005279/en/ContactsMEDIA CONTACTNaomi GoumilloutAgilent Technologies, Inc.+1.781.266.2819naomi.goumillout@agilent.com | Business Wire | 2023-06-05T12:00:00 | Agilent Announces Inspirational LC/TQ and LC/Q-TOF Mass Spectrometry Solutions at ASMS 2023 | https://finance.yahoo.com/news/agilent-announces-inspirational-lc-tq-120000928.html | ce10e349-390e-3f53-aa6d-338dda3991cb | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "SANTA CLARA, Calif., June 05, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced two new liquid chromatography mass spectrometry systems (LCMS), the Agilent 6495D LC/TQ and the Agilent Revident LC/Q-TOF. Facilitating the high-end performance of the Revident LC/Q-TOF, Agilent is also announcing the new Agilent MassHunter Explorer Profiling software and the new Agilent ChemVista library manager software.The superior Agilent 6495 Triple Quadrupole LC/MS (LC/TQ) System is ideal for demanding and challenging targeted analysis applications requiring the highest analytical sensitivity. The 6495 LC/TQ incorporates numerous intelligence features that address the critical transition between the ‘discovery phase’ of research and the ‘translational phase’ where studying a large volume of samples is crucial for generating meaningful scientific insights. The 6495 LC/TQ instrument was built for research with production-ready robustness, ensuring increased sample measurements due to greater efficiency and reduced instrument downtime. Intelligence features also include sub-millisecond dwell times and Intelligent Reflex that provides fast, sensitive, high-quality data, while early maintenance feedback and scheduled tuning keep the LC/TQ in peak working condition.The Agilent Revident Quadrupole Time-of-Flight LC/MS (LC/QTOF) System offers an entirely new instrument architecture coupled with instrument intelligence for maximized operation time and productivity. Revident is targeted toward food safety and environmental analysis but also has applications in other small molecule markets, from metabolomics to pharmaceuticals. Incorporating the new MassHunter Explorer Software, untargeted analyses are simplified by allowing data exploration, including statistical analysis and identification in a single software. Tasks can be performed faster with fewer errors and less expertise without compromising quality or accuracy. Additionally, the new ChemVista library manager software integrates extensive curated libraries. It enables third-party import and export into a tool that conveniently connects to MassHunter, allowing access to vast external databases for identification workflows.Story continues"The new 6495D LC/TQ offers significant improvements in sensitivity and speed over the current 6495C, which is already a reputable high-end LC/TQ, while the Revident LC/Q-TOF is the first of a new generation of LC/Q-TOF systems," said Sudharshana Seshadri, vice president and general manager of Agilent’s Liquid Chromatography, Mass Spectrometry, and Automation Divisions."This launch expands the instrument intelligence from our TQ product line to our Q-TOF. Revident also includes a novel detection system that greatly enhances spectral purity, and combined with our new MassHunter Explorer Profiling and ChemVista library manager software, the Revident LC/Q-TOF is revolutionizing our customers’ experience with LC/Q-TOF—providing the highest, yet relevant, performance for meaningful scientific insights," Seshadri added.Agilent is a leading solution provider of proven, robust, and reliable mass spectrometry technologies to a range of segments and a wide array of applications in the bio/pharma, life science research, food, and environmental markets. These new technological capabilities enable Agilent’s customers to increase data quality and interpretation while reducing the time and human attention required—more easily adapting to ever-changing market needs.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230605005279/en/ContactsMEDIA CONTACTNaomi GoumilloutAgilent Technologies, Inc.+1.781.266.2819naomi.goumillout@agilent.com"
Output: | 982 | true | 118.779999 | 117.440002 | 116.589996 | 114.690002 | 115.790001 | 118.540001 | DOWN | DOWN | DOWN | DOWN | DOWN | 0 | 0 | 0 | 0 | 0 | TRUE | 20 |
A | SANTA CLARA, Calif., June 06, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of the enhanced xCELLigence RTCA Software Pro Version 2.8, an integrated software package for running and analyzing real-time cell analysis data. This improved version enables Agilent xCELLigence Real-Time Cell Analysis (RTCA) systems in GMP-regulated facilities.The xCELLigence RTCA Software Pro enables data integrity controls to support regulatory requirements defined in FDA 21 CFR Part 11 and EU GMP Annex 11 for electronic records and electronic signatures, an essential requirement in pharmaceutical and biopharmaceutical manufacturing. New and enhanced features ensure that data and electronic records generated with xCELLigence RTCA systems are trustworthy, authentic, and reliable and meet GMP manufacturing compliance requirements.The xCELLigence RTCA system provides an essential functional potency assay in cell therapy development, manufacturing, and safety applications. Agilent instrumentation and software, alongside customer user organization controls, enables customers to meet FDA 21 CFR Part 11 and other applicable regulatory requirements. This system empowers customers to meet the demands of cell therapy discovery, process development, and QC-release criteria."The addition of compliance features to xCELLigence RTCA Software Pro ensures that Agilent xCELLigence RTCA systems meet the regulatory needs of our valued customers, especially in manufacturing and quality control settings," said Todd Christian, vice president and general manager of Agilent’s Cell Analysis Division. "This bridges the regulatory gap, and reinforces Agilent as a leading cell analysis solutions provider to the pharma and biopharma industries."Agilent’s key focus is to support customers’ regulatory requirements through our instrumentation and software applications. These solutions for compliant environments support immuno-oncology and cell and gene therapy customers, who are developing key components to address human health concerns, furthering Agilent’s core mission to advance the quality of human life.Story continuesAbout Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230606005547/en/ContactsNaomi GoumilloutAgilent Technologies+1.781.266.2819naomi.goumillout@agilent.com | Business Wire | 2023-06-06T12:00:00 | Agilent Announces Enhanced xCELLigence RTCA Software Pro to Support Regulatory Compliance Requirements | https://finance.yahoo.com/news/agilent-announces-enhanced-xcelligence-rtca-120000457.html | 7a48f48f-e900-3623-a74b-911650b99cc6 | false | Instruct: Given the article below, please indicate whether the price of the stock with ticker "A" will go up or down tomorrow. Only answer with UP or DOWN.
Tweet: "SANTA CLARA, Calif., June 06, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of the enhanced xCELLigence RTCA Software Pro Version 2.8, an integrated software package for running and analyzing real-time cell analysis data. This improved version enables Agilent xCELLigence Real-Time Cell Analysis (RTCA) systems in GMP-regulated facilities.The xCELLigence RTCA Software Pro enables data integrity controls to support regulatory requirements defined in FDA 21 CFR Part 11 and EU GMP Annex 11 for electronic records and electronic signatures, an essential requirement in pharmaceutical and biopharmaceutical manufacturing. New and enhanced features ensure that data and electronic records generated with xCELLigence RTCA systems are trustworthy, authentic, and reliable and meet GMP manufacturing compliance requirements.The xCELLigence RTCA system provides an essential functional potency assay in cell therapy development, manufacturing, and safety applications. Agilent instrumentation and software, alongside customer user organization controls, enables customers to meet FDA 21 CFR Part 11 and other applicable regulatory requirements. This system empowers customers to meet the demands of cell therapy discovery, process development, and QC-release criteria."The addition of compliance features to xCELLigence RTCA Software Pro ensures that Agilent xCELLigence RTCA systems meet the regulatory needs of our valued customers, especially in manufacturing and quality control settings," said Todd Christian, vice president and general manager of Agilent’s Cell Analysis Division. "This bridges the regulatory gap, and reinforces Agilent as a leading cell analysis solutions provider to the pharma and biopharma industries."Agilent’s key focus is to support customers’ regulatory requirements through our instrumentation and software applications. These solutions for compliant environments support immuno-oncology and cell and gene therapy customers, who are developing key components to address human health concerns, furthering Agilent’s core mission to advance the quality of human life.Story continuesAbout Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230606005547/en/ContactsNaomi GoumilloutAgilent Technologies+1.781.266.2819naomi.goumillout@agilent.com"
Output: | 686 | true | 117.169998 | 116.589996 | 114.690002 | 115.790001 | 118.540001 | 119.5 | DOWN | DOWN | DOWN | UP | UP | 0 | 0 | 0 | 1 | 1 | TRUE | 21 |
End of preview. Expand in Data Studio
- Downloads last month
- 3